UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~FORM 10-Q~~



ý☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2017~~March 31, 2023



¨☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-5975

HUMANA INC.


(Exact name of registrant as specified in its charter)



Delaware						61-0647538
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification ~~Number)~~ No.)

500 West Main Street

Louisville, Kentucky 40202

(Address of principal executive offices, including zip code)

(502) 580-1000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.16 2/3 par value	HUM	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý☒ No ¨☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ý☒ No ¨☐

Indicate by ~~checkmark~~check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. ~~(Check one):~~

Large accelerated filer

☒

Accelerated filer

☐

~~Large accelerated filer~~

~~Accelerated filer~~

Non-accelerated filer

¨☐

Smaller reporting company

¨☐

Emerging growth company

¨☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨☐ No ý☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.



Class of Common Stock			Outstanding at ~~September 30, 2017~~ March 31, 2023
$0.16 2/3 par value			~~142,860,096~~124,944,994 shares

Table of Contents

Humana Inc.

FORM 10-Q

~~SEPTEMBER 30, 2017~~MARCH 31, 2023

INDEX


				Page
Part I: Financial Information
Item 1.		Financial Statements

			~~Page~~
~~Part I: Financial Information~~
~~Item 1.~~	~~Financial Statements (Unaudited)~~

	Condensed Consolidated Balance Sheets (Unaudited) at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016~~202 2		3

		Condensed Consolidated Statements of Income (Unaudited) for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016~~202 2		4

		Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016~~202 2		5

		Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three months ended March 3 1, 2023 and 2022		6

		Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~nine~~three months ended ~~September 30, 2017~~M arch 31, 2023 and ~~2016~~202 2		67

		Notes to Condensed Consolidated Financial Statements (Unaudited)		79

Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations		3733

Item 3.		Quantitative and Qualitative Disclosures about Market Risk		6249

Item 4.		Controls and Procedures		6249

Part II: Other Information

Item 1.		Legal Proceedings		6350

Item 1A.		Risk Factors		6350

Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds		6350

Item 3.		Defaults Upon Senior Securities		6450

Item 4.		Mine Safety Disclosures		6450

Item 5.		Other Information		6450

Item 6.		Exhibits		6451

		Signatures		6552

		Certifications

Humana Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	March 31, 2023		December 31, 2022
	(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	13,735	$	5,061
Investment securities	14,932		13,881
Receivables, net of allowances of $69 in 2023 and $70 in 2022	3,107		1,674
Other current assets	5,758		5,567

Total current assets	37,532		26,183
Property and equipment, net	3,234		3,221
Long-term investment securities	371		380
Equity method investments	739		749
Goodwill	9,320		9,142
Other long-term assets	3,580		3,380

Total assets	$	54,776	$	43,055
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable	$	10,018	$	9,264
Trade accounts payable and accrued expenses	7,431		5,238
Book overdraft	406		298
Unearned revenues	7,220		286
Short-term debt	1,867		2,092

Total current liabilities	26,942		17,178
Long-term debt	9,743		9,034
Other long-term liabilities	1,457		1,473

Total liabilities	38,142		27,685

Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	—		—
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at March 31, 2023 and December 31, 2022	33		33
Capital in excess of par value	3,262		3,246
Retained earnings	26,619		25,492
Accumulated other comprehensive loss	(1,113)		(1,304)
Treasury stock, at cost, 73,721,604 shares at March 31, 2023 and 73,691,955 shares at December 31, 2022	(12,224)		(12,156)
Total stockholders' equity	16,577		15,311
Noncontrolling interests	57		59
Total equity	16,634		15,370
Total liabilities and equity	$	54,776	$	43,055

September 30,
2017 December 31,
2016
(in millions, except share amounts)
ASSETS

Current assets:
Cash and cash equivalents $ 9,865
$ 3,877
Investment securities 8,622
7,595
Receivables, less allowance for doubtful accounts of $89 in 2017
and $118 in 2016 922
1,280
Other current assets 3,776
3,438
Total current assets 23,185
16,190
Property and equipment, net 1,560
1,505
Long-term investment securities 2,716
2,203
Goodwill 3,281
3,272
Other long-term assets 2,214
2,226
Total assets $ 32,956
$ 25,396
LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Benefits payable $ 4,959
$ 4,563
Trade accounts payable and accrued expenses 4,888
2,467
Book overdraft 171
212
Unearned revenues 3,447
280
Short-term debt 953
300
Total current liabilities 14,418
7,822
Long-term debt 3,977
3,792
Future policy benefits payable 2,893
2,834
Other long-term liabilities 457
263
Total liabilities 21,745
14,711
Commitments and contingencies

Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued —
—
Common stock, $0.16 2/3 par; 300,000,000 shares authorized;
198,572,158 shares issued at September 30, 2017 and 198,495,007 shares
issued at December 31, 2016 33
33
Capital in excess of par value 2,641
2,562
Retained earnings 13,542
11,454
Accumulated other comprehensive income (loss) 12
(66 )
Treasury stock, at cost, 55,712,062 shares at September 30, 2017 and
49,189,811 shares at December 31, 2016 (5,017 ) (3,298 )
Total stockholders’ equity 11,211
10,685
Total liabilities and stockholders’ equity $ 32,956
$ 25,396

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three months ended September 30,				Nine months ended September 30,						Three months ended March 31,
	2017		2016		2017			2016			2023		2022
	(in millions, except per share results)										(in millions, except per share results)
Revenues:										Revenues:
Premiums	$	12,955	$	13,371	$	39,556		$	40,461	Premiums	$	25,550	$	22,703
Services	223		227		706			749		Services	999		1,264
Investment income	104		96		316			291		Investment income	193		3
Total revenues	13,282		13,694		40,578			41,501		Total revenues	26,742		23,970
Operating expenses:										Operating expenses:
Benefits	10,642		10,900		32,857			33,806		Benefits	21,858		19,625
Operating costs	1,688		1,739		4,694			5,172		Operating costs	2,979		2,886
Merger termination fee and related costs, net	—		20		(947		)	81
Depreciation and amortization	94		86		278			263		Depreciation and amortization	186		170
Total operating expenses	12,424		12,745		36,882			39,322		Total operating expenses	25,023		22,681
Income from operations	858		949		3,696			2,179		Income from operations	1,719		1,289

Interest expense	59		47		166			141		Interest expense	113		90
Income before income taxes	799		902		3,530			2,038
Other income, net										Other income, net	(8)		(21)
Income before income taxes and equity in net losses										Income before income taxes and equity in net losses	1,614		1,220
Provision for income taxes	300		452		1,266			1,023		Provision for income taxes	359		286
Equity in net losses										Equity in net losses	(17)		(4)
Net income	$	499	$	450	$	2,264		$	1,015	Net income	$	1,238	$	930
Net loss attributable to noncontrolling interests										Net loss attributable to noncontrolling interests	1		—
Net income attributable to Humana										Net income attributable to Humana	$	1,239	$	930
Basic earnings per common share	$	3.46	$	3.01	$	15.56		$	6.80	Basic earnings per common share	$	9.91	$	7.32
Diluted earnings per common share	$	3.44	$	2.98	$	15.44		$	6.73	Diluted earnings per common share	$	9.87	$	7.29
Dividends declared per common share	$	0.40	$	0.29	$	1.20		$	0.87

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

Three months ended
September 30, Nine months ended
September 30,
2017 2016 2017 2016
(in millions)
Net income $ 499
$ 450
$ 2,264
$ 1,015
Other comprehensive income:
Change in gross unrealized investment
gains/losses 26
(9 ) 152
150
Effect of income taxes (9 ) 3
(56 ) (55 )
Total change in unrealized
investment gains/losses, net of tax 17
(6 ) 96
95
Reclassification adjustment for net
realized gains included in
investment income —
(26 ) (28 ) (65 )
Effect of income taxes —
10
10
24
Total reclassification adjustment, net
of tax —
(16 ) (18 ) (41 )
Other comprehensive income (loss), net
of tax 17
(22 ) 78
54
Comprehensive income $ 516
$ 428
$ 2,342
$ 1,069


	Three months ended March 31,
	2023		2022
	(in millions)
Net income attributable to Humana	$	1,239	$	930
Other comprehensive income (loss):
Change in gross unrealized investment gains (losses)	188		(769)
Effect of income taxes	(43)		176
Total change in unrealized investment gains (losses), net of tax	145		(593)
Reclassification adjustment for net realized losses (gains)	61		(27)
Effect of income taxes	(15)		6
Total reclassification adjustment, net of tax	46		(21)
Other comprehensive income (loss), net of tax	191		(614)


Comprehensive income attributable to Humana	$	1,430	$	316

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Common Stock			Capital In Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive Income (loss)		Treasury Stock		Total Stockholders' Equity		Noncontrolling Interests		Total Equity
	Issued Shares	Amount
	(dollars in millions, share amounts in thousands)
Three months ended March 31, 2023
Balances, December 31, 2022	198,667	$	33	$	3,246	$	25,492	$	(1,304)	$	(12,156)	$	15,311	$	59	$	15,370
Net income						1,239						1,239		(1)		1,238
Distribution from noncontrolling interest holders, net														4		4

Acquisition														(5)		(5)
Other comprehensive income								191				191				191
Common stock repurchases				—						(94)		(94)				(94)
Dividends and dividend equivalents				—		(112)						(112)				(112)
Stock-based compensation				38								38				38
Restricted stock unit vesting	—	—		(24)						24		—				—
Stock option exercises	—	—		2						2		4				4
Balances, March 31, 2023	198,667	$	33	$	3,262	$	26,619	$	(1,113)	$	(12,224)	$	16,577	$	57	$	16,634

Three months ended March 31, 2022
Balances, December 31, 2021	198,649	$	33	$	3,082	$	23,086	$	42	$	(10,163)	$	16,080	$	23	$	16,103
Net income						930						930		—		930



Other comprehensive loss								(614)				(614)				(614)
Common stock repurchases				—						(1,024)		(1,024)				(1,024)
Dividends and dividend equivalents				—		(101)						(101)				(101)
Stock-based compensation				43								43				43
Restricted stock unit vesting	—	—		(24)						24		—				—
Stock option exercises	—	—		2						3		5				5
Balances, March 31, 2022	198,649	$	33	$	3,103	$	23,915	$	(572)	$	(11,160)	$	15,319	$	23	$	15,342

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	For the three months ended March 31,
	2023		2022
	(in millions)
Cash flows from operating activities
Net income	$	1,238	$	930
Adjustments to reconcile net income to net cash provided by operating activities:

Loss on investment securities, net	60		76

Equity in net losses	17		4
Stock-based compensation	38		43
Depreciation	200		181
Amortization	18		24


Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:
Receivables	(1,433)		(1,360)
Other assets	(907)		(628)
Benefits payable	754		1,089
Other liabilities	(238)		(103)
Unearned revenues	6,934		34
Other	6		12
Net cash provided by operating activities	6,687		302
Cash flows from investing activities

Acquisitions, net of cash and cash equivalents acquired	(73)		(74)
Purchases of property and equipment, net	(223)		(295)
Purchases of investment securities	(1,313)		(2,161)
Proceeds from maturities of investment securities	267		588
Proceeds from sales of investment securities	50		1,294
Net cash used in investing activities	(1,292)		(648)
Cash flows from financing activities
Receipts from contract deposits, net	2,997		2,475
Proceeds from issuance of senior notes, net	1,215		744
Repayments of senior notes	(60)		—
Repayments from issuance of commercial paper, net	(177)		(265)

Repayment of term loan	(500)		—
Debt issue costs	(4)		(1)
Change in book overdraft	108		(9)
Common stock repurchases	(94)		(1,024)
Dividends paid	(100)		(91)
Other	(106)		(13)
Net cash provided by financing activities	3,279		1,816
Increase in cash and cash equivalents	8,674		1,470
Cash and cash equivalents at beginning of period	5,061		3,394
Cash and cash equivalents at end of period	$	13,735	$	4,864

For the nine months ended
September 30,
2017 2016
(in millions)
Cash flows from operating activities
Net income $ 2,264
$ 1,015
Adjustments to reconcile net income to net cash provided by
operating activities:
Net realized capital gains (28 ) (65 )
Stock-based compensation 116
76
Depreciation 303
289
Other intangible amortization 54
59
(Benefit) provision for deferred income taxes (54 ) 54
Changes in operating assets and liabilities, net of effect of
businesses acquired and dispositions:
Receivables 358
396
Other assets (369 ) (419 )
Benefits payable 396
73
Other liabilities 641
127
Unearned revenues 3,167
2,987
Other, net 114
117
Net cash provided by operating activities 6,962
4,709
Cash flows from investing activities
Acquisitions, net of cash acquired (10 ) (7 )
Purchases of property and equipment (376 ) (395 )
Purchases of investment securities (4,337 ) (4,533 )
Maturities of investment securities 919
1,082
Proceeds from sales of investment securities 2,028
3,319
Net cash used in investing activities (1,776 ) (534 )
Cash flows from financing activities
Receipts from contract deposits, net 1,931
350
Proceeds from issuance of senior notes, net 985
—
Repayment of commercial paper, net (153 ) (1 )
Change in book overdraft (41 ) (118 )
Common stock repurchases (1,819 ) (75 )
Dividends paid (162 ) (133 )
Proceeds from stock option exercises and other 61
—
Net cash provided by financing activities 802
23
Increase in cash and cash equivalents 5,988
4,198
Cash and cash equivalents at beginning of period 3,877
2,571
Cash and cash equivalents at end of period $ 9,865
$ 6,769
Supplemental cash flow disclosures:
Interest payments $ 124
$ 102
Income tax payments, net $ 1,206
$ 851

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)

(Unaudited)


	For the three months ended March 31,
	2023		2022
	(in millions)
Supplemental cash flow disclosures:
Interest payments	$	97	$	67
Income tax payments (refund), net	$	6	$	(20)
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired	$	73	$	84
Less: Fair value of liabilities assumed	(5)		(10)
Less: Noncontrolling interests acquired	5		—

Cash paid for acquired businesses, net of cash and cash equivalents acquired	$	73	$	74

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, ~~2016,~~2022, that was filed with the Securities and Exchange Commission, or the SEC, on February ~~17, 2017.~~16, 2023. We refer to ~~the~~this Form 10-K as the ~~“2016~~“2022 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of ~~benefits payable, future policy~~ benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including ~~goodwill.~~goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. ~~Refer~~For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the ~~consolidated financial statements~~audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our ~~2016~~2022 Form ~~10-K for information on accounting policies that we consider in preparing our consolidated financial statements.~~10-K.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

~~Sale~~Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of ~~Closed Block~~commercial members over the long term or support our long-term strategic plans. The exit from this line of ~~Commercial Long-Term Care Insurance Business~~business will be phased over the next 18 to 24 months.

~~On November 6, 2017, we entered into a definitive agreement~~

Value Creation Initiatives

During 2022, in order to ~~sell the stock~~create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our ~~wholly-owned subsidiary, KMG America Corporation, or KMG,~~healthcare services capabilities in 2023, we committed to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG’s subsidiary, Kanawha Insurance Company, or KIC, includes our closed block of non-strategic commercial long-term care insurance policies. Based ondrive additional value for the terms of the definitive agreement we expect to record a net loss associated with the sale of KMG of approximately $400 million. The estimated loss includes a pretax loss of approximately $900 million, offset by the expected tax benefit of approximately $500 million. We will fund the transaction with approximately $203 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately$150 million of statutory capital with the sale, which together should be more than offset by the estimated $500 million cash savings associated with the expected tax treatment of the sale. The KMG transaction is anticipated to close by the third quarter of 2018 subject to customary closing conditions, including South Carolina Department of Insurance approval. There can be no assurance we will obtain regulatory approvals needed to sell the business or do so under terms acceptable to us.

~~Workforce Optimization~~

~~During the third quarter of 2017, we initiated a voluntary early retirement program~~enterprise through cost saving, productivity initiatives, and ~~an involuntary workforce reduction program. These programs are expected to impact approximately 2,700 associates, or 5.7%, of our workforce.~~value acceleration from previous investments. As a result of these initiatives, we recorded ~~estimated~~ charges of ~~$124~~$473 million ~~or $0.54 per diluted common share. At October~~for the year-ended December 31, ~~2017, we had approximately 47,200 employees.~~2022. These charges primarily relate to $248 million in asset impairments, including software and abandonment, and $116 million of severance charges in connection with workforce optimization. The ~~estimated~~remainder of the charges primarily relate to external consulting fees. These charges were recorded at the corporate level and not allocated to the segments. ~~This charge is included with operating costs~~We did not record any charges in the condensed consolidated statements of income for the three and nine month periods ended September 30, 2017. Payments under these programs are made upon termination during the early retirement or severance pay period, primarily starting as of the beginning of the first quarter of ~~2018. We expect this liability to be primarily paid within the next 12 months and classified it as a current liability, included~~2022, with no recurring charges in ~~trade accounts payable and accrued expenses.~~ 2023.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

COVID-19

~~Aetna Merger~~The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. During periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

~~On July 2, 2015, we entered into an Agreement~~The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and ~~Plan~~the Public Health Emergency is set to expire on May 11, 2023.

Revenue Recognition

Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of ~~Merger, which we~~members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in ~~this report as the Merger Agreement, with Aetna Inc.~~Part II, Item 8, "Financial Statements and ~~certain wholly owned subsidiaries~~Supplementary Data" in our 2022 Form 10-K. For additional information regarding disaggregation of ~~Aetna Inc., which we~~revenue by segment and type, refer to ~~collectively as Aetna, which set forth~~Note 14 to the ~~terms and conditions under which we agreed to merge with, and become a wholly owned subsidiary of Aetna, a transaction we refer to in this report as the Merger.~~

The Merger was subject to customary closing conditions, including, among other things, (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of necessary approvals under state insurance and healthcare laws and regulations and pursuant to certain licenses of certain of Humana’s subsidiaries, and (ii) the absence of legal restraints and prohibitions on the consummation of the Merger.

On July 21, 2016, the U.S. Department of Justice and the attorneys general of certain U.S. jurisdictions filed a civil antitrust complaint in the U.S. District Court for the District of Columbia against us and Aetna, alleging that the Merger would violate Section 7 of the Clayton Antitrust Act and seeking a permanent injunction to prevent the Merger from being completed. On January 23, 2017, the Court ruled in favor of the DOJ and granted a permanent injunction of the proposed transaction. On February 14, 2017, we and Aetna agreed to mutually terminate the Merger Agreement, as our Board determined that an appeal of the Court's ruling would not be in the best interest of our stockholders. On February 16, 2017, under the terms of the Merger Agreement, we received a breakup fee of $1 billion from Aetna, which isunaudited Condensed Consolidated Financial Statements included in ~~our condensed consolidated statement~~Part I, Item 1, "Financial Statements" of ~~income in the line captioned Merger termination fee and~~this Form 10-Q.

At March 31, 2023, accounts receivable related ~~costs, net. Prior period Merger related transaction costs, previously included in operating costs, have been reclassified~~ to ~~conform to the 2017 presentation.~~

~~Business Segment Reclassifications~~

~~During~~services were $246 million. For the three months ended March 31, ~~2017,~~2023, we ~~realigned certain of our businesses among our reportable segments~~had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at March 31, 2023.

For the three months ended March 31, 2023, services revenue recognized from performance obligations related to ~~correspond with internal management reporting~~prior periods, such as due to changes and our previously announced planned exit from the Individual Commercial medical business on January 1, 2018. Additionally, we renamed our Group segment to the Group and Specialty segment, and began presenting the Individual Commercial business results as a separate segment rather than as part of the Retail segment. Specialty health insurance benefits, including dental, vision, other supplement health, and financial protection products, marketed to individuals are now included in ~~the Group and Specialty segment. Specialty health insurance benefits marketed to employer groups continue~~transaction price, was not material. Further, services revenue expected to be ~~included~~recognized in the Group and Specialty segment. As a result of this realignment, our reportable segments now include Retail, Group and Specialty, Healthcare Services, and Individual Commercial. Prior period segment financial information has been recastany future year related to ~~conform to the 2017 presentation. See Note 15 for segment financial information.~~remaining performance obligations was not material.

2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In ~~May 2014,~~November 2020, the ~~Financial~~FASB issued Accounting Standards ~~Board, or FASB,~~Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance ~~that amends the~~relates to accounting for ~~revenue recognition. The amendments are intended to provide a more robust framework for addressing revenue issues, improve comparability~~long-duration contracts of revenue recognition practices, and improve disclosure requirements. Insurance contracts are not included in the scope of this new guidance. Accordingly, our premiums revenue and investment income, collectively representing approximately 98% of our consolidated external revenues for 2016, are not included in the scopeinsurers which revises key elements of the ~~new guidance. We will adopt~~measurement models and disclosure requirements for long-duration contracts issued by insurers, including the ~~guidance~~amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using ~~the modified retrospective approach with a cumulative effect adjustment, if any, to retained earnings. We are analyzing how we may recognize revenue under the~~current, rather than locked-in, assumptions. The new guidance, ~~by reviewing selected sample contracts presently in place. While we expect revenue related~~limited to our ~~Pharmacy, Provider Services, ASO~~Medicare Supplement product which represent less than 1% of consolidated premiums and ~~other~~ services ~~businesses~~revenue, became effective for us beginning January 1, 2023 and is to ~~remain primarily unchanged, we are still reviewing~~be applied to contracts in force on the ~~impact~~basis of their existing carrying value amounts at the beginning of the ~~new guidance on the customer arrangements for these businesses. Accordingly, we continue to evaluate the impact~~earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial ~~condition,~~position or cash ~~flows, and disclosures. The new guidance is effective for us beginning with annual and interim periods in 2018.~~flows.

~~In February 2016, the FASB issued new guidance related to accounting for leases which requires lessees to record~~

Table of Contents

assets and liabilities reflecting the leased assets and lease obligations, respectively, while following the dual model for recognition in statements of income requiring leases to be classified as either operating or finance. Operating leases

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). The new guidance is effective for us beginning with annual and interim periods in 2019, with earlier adoption permitted, and requires retrospective application to previously issued annual and interim financial statements. We have begun the process of identifying the population of lease agreements and other arrangements that may contain embedded leases for purposes of adopting the new standard. While we expect to record significant leased assets and corresponding lease obligations based on our existing population of individual leases, we continue to evaluate the impact on our results of operations, financial position and cash flows.

In June 2016, the FASB issued guidance introducing a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance is effective for us beginning January 1, 2020. The new current expected credit losses (CECL) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The

~~new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses~~

~~on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions~~

in the amortized cost of the securities, and provides for additional disclosure requirements. Our investment portfolio consists of available-for-sale debt securities. We are currently evaluating the impact on our results of operations, financial condition, or cash flows.

In January 2017, the FASB issued guidance which simplifies the accounting for goodwill impairment. The new guidance eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. A goodwill impairment charge would be recognized if the carrying amount of a reporting unit exceeds the estimated fair value of the reporting unit. The new guidance is effective for us beginning with annual and interim periods in 2020, with early adoption permitted, and is to be applied prospectively. The adoption of this new guidance is not expected to have a material impact on our financial position or operating results.

In March 2017, the FASB issued new guidance that amends the accounting for premium amortization on purchased callable debt securities by shortening the amortization period. This amended guidance requires the premium to be amortized to the earliest call date instead of maturity date. The new guidance is effective for us beginning with annual and interim periods in 2019. We do not expect adoption of this guidance will have a material impact on our results of operations, financial condition and cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

3. ACQUISITIONS AND DIVESTITURES

On August 11, 2022, we completed the sale of a 60% interest in Gentiva, formerly Kindred, Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $237 million. For the three months ended March 31, 2022, the accompanying condensed consolidated statement of income includes revenues related to Gentiva Hospice of $382 million and pretax earnings of $62 million.

During ~~2017~~2023 and ~~2016,~~2022, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2023 and 2022 have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in ~~2017~~2023 and ~~2016~~2022 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

4. INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016,~~2022, respectively:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	(in millions)
March 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,394	$	9	$	(47)	$	1,356
Mortgage-backed securities	3,919		7		(423)		3,503
Tax-exempt municipal securities	762		1		(27)		736
Mortgage-backed securities:
Residential	470		—		(73)		397
Commercial	1,562		—		(149)		1,413
Asset-backed securities	1,915		2		(64)		1,853
Corporate debt securities	6,725		16		(696)		6,045
Total debt securities	$	16,747	$	35	$	(1,479)	15,303
Common stock							—
Total investment securities							$	15,303

December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	1,093	$	1	$	(55)	$	1,039
Mortgage-backed securities	3,697		4		(471)		3,230
Tax-exempt municipal securities	765		0		(37)		728
Mortgage-backed securities:
Residential	477		—		(76)		401
Commercial	1,554		—		(155)		1,399
Asset-backed securities	1,809		1		(79)		1,731
Corporate debt securities	6,551		3		(828)		5,726
Total debt securities	$	15,946	$	9	$	(1,701)	14,254
Common stock							7
Total investment securities							$	14,261

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair
Value
(in millions)
September 30, 2017
U.S. Treasury and other U.S. government
corporations and agencies:
U.S. Treasury and agency obligations $ 821
$ 1
$ (8 ) $ 814
Mortgage-backed securities 1,423
5
(19 ) 1,409
Tax-exempt municipal securities 3,457
28
(16 ) 3,469
Mortgage-backed securities:
Residential 7
—
—
7
Commercial 399
3
(2 ) 400
Asset-backed securities 140
—
—
140
Corporate debt securities 4,921
215
(37 ) 5,099
Total debt securities $ 11,168
$ 252
$ (82 ) $ 11,338

December 31, 2016
U.S. Treasury and other U.S. government
corporations and agencies:
U.S. Treasury and agency obligations $ 800
$ 1
$ (15 ) $ 786
Mortgage-backed securities 1,662
6
(31 ) 1,637
Tax-exempt municipal securities 3,358
15
(68 ) 3,305
Mortgage-backed securities:
Residential 9
—
—
9
Commercial 307
1
(4 ) 304
Asset-backed securities 160
—
—
160
Corporate debt securities 3,530
145
(78 ) 3,597
Total debt securities $ 9,826
$ 168
$ (196 ) $ 9,798

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We held certain corporate debt securities of Gentiva Hospice at March 31, 2023 with amortized cost and fair value of approximately $281 million and $286 million, respectively.

Gross unrealized losses and fair values aggregated by investment category and length of time ~~that~~of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016,~~2022, respectively:


	Less than 12 months				12 months or more				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
	(in millions)
March 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	290	$	(2)	$	396	$	(45)	$	686	$	(47)
Mortgage-backed securities	867		(17)		2,123		(406)		2,990		(423)
Tax-exempt municipal securities	343		(5)		314		(22)		657		(27)
Mortgage-backed securities:
Residential	25		(2)		369		(71)		394		(73)
Commercial	119		(4)		1,275		(145)		1,394		(149)
Asset-backed securities	583		(21)		971		(43)		1,554		(64)
Corporate debt securities	1,453		(47)		3,634		(649)		5,087		(696)
Total debt securities	$	3,680	$	(98)	$	9,082	$	(1,381)	$	12,762	$	(1,479)

December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	$	512	$	(5)	$	397	$	(50)	$	909	$	(55)
Mortgage-backed securities	1,231		(104)		1,683		(367)		2,914		(471)
Tax-exempt municipal securities	64		(2)		615		(36)		679		(38)
Mortgage-backed securities:
Residential	124		(16)		274		(60)		398		(76)
Commercial	243		(13)		1,157		(142)		1,400		(155)
Asset-backed securities	620		(32)		1,011		(46)		1,631		(78)
Corporate debt securities	1,625		(98)		3,825		(730)		5,450		(828)
Total debt securities	$	4,419	$	(270)	$	8,962	$	(1,431)	$	13,381	$	(1,701)

Less than 12 months 12 months or more Total
Fair
Value Gross
Unrealized
Losses Fair
Value Gross
Unrealized
Losses Fair
Value Gross
Unrealized
Losses
(in millions)
September 30, 2017
U.S. Treasury and other U.S.
government corporations
and agencies:
U.S. Treasury and agency
obligations $ 522
$ (5 ) $ 137
$ (3 ) $ 659
$ (8 )
Mortgage-backed
securities 986
(17 ) 82
(2 ) 1,068
(19 )
Tax-exempt municipal
securities 1,320
(9 ) 460
(7 ) 1,780
(16 )
Mortgage-backed securities:
Residential —
—
4
—
4
—
Commercial 115
(2 ) —
—
115
(2 )
Asset-backed securities 64
—
—
—
64
—
Corporate debt securities 999
(15 ) 469
(22 ) 1,468
(37 )
Total debt securities $ 4,006
$ (48 ) $ 1,152
$ (34 ) $ 5,158
$ (82 )

December 31, 2016
U.S. Treasury and other U.S.
government corporations
and agencies:
U.S. Treasury and agency
obligations $ 697
$ (15 ) $ 3
$ —
$ 700
$ (15 )
Mortgage-backed
securities 1,528
(31 ) 3
—
1,531
(31 )
Tax-exempt municipal
securities 2,756
(67 ) 43
(1 ) 2,799
(68 )
Mortgage-backed securities:
Residential —
—
4
—
4
—
Commercial 182
(3 ) 24
(1 ) 206
(4 )
Asset-backed securities 51
—
63
—
114
—
Corporate debt securities 1,544
(71 ) 69
(7 ) 1,613
(78 )
Total debt securities $ 6,758
$ (187 ) $ 209
$ (9 ) $ 6,967
$ (196 )

Approximately 98% of our debt securities were investment-grade quality, with a weighted average credit rating of AA by Standard & Poor's Rating Service, or S&P, at ~~September 30, 2017.~~March 31, 2023. Most of the debt securities that were below investment-grade were rated ~~BB,~~BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding ~~9%. In addition, 2%~~1% of our ~~tax-exempt securities were insured by bond insurers and had an~~

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~equivalent weighted average S&P credit rating of AA exclusive of the bond insurers’ guarantee.~~total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

Our unrealized losses from all debt securities were generated from approximately ~~680~~1,550 positions out of a total of approximately ~~2,320~~1,950 positions at ~~September 30, 2017.~~March 31, 2023. All issuers of debt securities we own that were trading at an unrealized loss at ~~September 30, 2017~~March 31, 2023 remain current on all contractual payments. After taking into account these and

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time ~~the~~these debt securities were purchased. At ~~September 30, 2017,~~March 31, 2023, we did not intend to sell ~~the~~any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. ~~As a result,~~Additionally, we ~~believe~~did not record any material credit allowances for debt securities that ~~the securities with~~were in an unrealized loss ~~were not other-than-temporarily impaired at September 30, 2017.~~position for the three months ended March 31, 2023 or 2022.

The detail of ~~realized~~(losses) gains ~~(losses)~~ related to investment securities and included within investment income was as follows for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016:~~2022:


	Three months ended March 31,
	2023		2022
	(in millions)
Gross gains on investment securities	$	—	$	33
Gross losses on investment securities	(61)		(1)
Gross gains on equity securities	1		—
Gross losses on equity securities	—		(108)
Net recognized losses on investment securities	$	(60)	$	(76)

Three months ended
September 30, Nine months ended
September 30,
2017 2016 2017 2016
(in millions)
Gross realized gains $ 3
$ 37
$ 34
$ 88
Gross realized losses (3 ) (11 ) (6 ) (23 )
Net realized capital gains $ —
$ 26

$ 28

$ 65

~~There were no material other-than-temporary impairments~~The gains and losses related to equity securities for the three ~~and nine~~ months ended ~~September 30, 2017 or 2016.~~March 31, 2023 and 2022 was as follows:


	Three months ended March 31,
	2023		2022
	(in millions)
Net gains (losses) recognized on equity securities during the period	$	1	$	(108)
Less: Net gains (losses) recognized on equity securities sold during the period	1		(59)
Unrealized losses recognized on equity securities still held at the end of the period	$	—	$	(49)

The contractual maturities of debt securities available for sale at ~~September 30, 2017,~~March 31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.


	Amortized Cost		Fair Value
	(in millions)
Due within one year	$	500	$	495
Due after one year through five years	4,116		3,941
Due after five years through ten years	3,014		2,650
Due after ten years	1,251		1,051
Mortgage and asset-backed securities	7,866		7,166
Total debt securities	$	16,747	$	15,303

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Amortized
Cost Fair
Value
(in millions)
Due within one year $ 501
$ 502
Due after one year through five years 2,999
3,014
Due after five years through ten years 2,555
2,561
Due after ten years 3,144
3,305
Mortgage and asset-backed securities 1,969
1,956
Total debt securities $ 11,168
$ 11,338

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

5. FAIR VALUE

Financial Assets

The following table summarizes our fair value measurements at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016,~~2022, respectively, for financial assets measured at fair value on a recurring basis:


	Fair Value Measurements Using
	Fair Value		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
	(in millions)
March 31, 2023
Cash equivalents	$	13,613	$	13,613	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	1,356		—		1,356		—
Mortgage-backed securities	3,503		—		3,503		—
Tax-exempt municipal securities	736		—		736		—
Mortgage-backed securities:
Residential	397		—		397		—
Commercial	1,413		—		1,413		—
Asset-backed securities	1,853		—		1,853		—
Corporate debt securities	6,045		—		5,946		99
Total debt securities	15,303		—		15,204		99
Common stock	—		—		—		—
Total invested assets	$	28,916	$	13,613	$	15,204	$	99

December 31, 2022
Cash equivalents	$	4,832	$	4,832	$	—	$	—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations	1,039		—		1,039		—
Mortgage-backed securities	3,230		—		3,230		—
Tax-exempt municipal securities	728		—		728		—
Mortgage-backed securities:
Residential	401		—		401		—
Commercial	1,399		—		1,399		—
Asset-backed securities	1,731		—		1,731		—
Corporate debt securities	5,726		—		5,625		101
Total debt securities	14,254		—		14,153		101
Common stock	7		7		—		—
Total invested assets	$	19,093	$	4,839	$	14,153	$	101

Fair Value Measurements Using
Fair
Value Quoted Prices
in Active
Markets
(Level 1) Other
Observable
Inputs
(Level 2) Unobservable
Inputs
(Level 3)
(in millions)
September 30, 2017
Cash equivalents $ 9,368
$ 9,368
$ —
$ —
Debt securities:
U.S. Treasury and other U.S. government
corporations and agencies:
U.S. Treasury and agency obligations 814
—
814
—
Mortgage-backed securities 1,409
—
1,409
—
Tax-exempt municipal securities 3,469
—
3,469
—
Mortgage-backed securities:
Residential 7
—
7
—
Commercial 400
—
400
—
Asset-backed securities 140
—
140
—
Corporate debt securities 5,099
—
5,098
1
Total debt securities 11,338
—
11,337
1
Total invested assets $ 20,706
$ 9,368
$ 11,337
$ 1

December 31, 2016
Cash equivalents $ 3,654
$ 3,654
$ —
$ —
Debt securities:
U.S. Treasury and other U.S. government
corporations and agencies:
U.S. Treasury and agency obligations 786
—
786
—
Mortgage-backed securities 1,637
—
1,637
—
Tax-exempt municipal securities 3,305
—
3,302
3
Mortgage-backed securities:
Residential 9
—
9
—
Commercial 304
—
304
—
Asset-backed securities 160
—
160
—
Corporate debt securities 3,597
—
3,593
4
Total debt securities 9,798
—
9,791
7
Total invested assets $ 13,452
$ 3,654
$ 9,791
$ 7

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

~~There were no material transfers between Level 1 and Level 2 during the three and nine months ended September 30, 2017 or 2016.~~

Our Level 3 assets had a fair value of $1$99 million at ~~September 30, 2017, less than 0.01%~~March 31, 2023, or 0.3% of our total invested assets. During the ~~three and nine months~~year ended ~~September 30, 2017 and 2016,~~March 31, 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

For the three months ended September 30,
2017 2016
Private
Placements Auction
Rate
Securities Total Private
Placements Auction
Rate
Securities Total
(in millions)
Beginning balance at July 1 $ 4
$ —
$ 4
$ 6
$ 3
$ 9
Sales (3 ) —
(3 ) —
—
—
Balance at September 30 $ 1
$ —
$ 1
$ 6
$ 3
$ 9

For the nine months ended September 30,
2017 2016
Private
Placements Auction
Rate
Securities Total Private
Placements Auction
Rate
Securities Total
(in millions)
Beginning balance at January 1 $ 4
$ 3
$ 7
$ 6
$ 5
$ 11
Sales (3 ) —
(3 ) —
—
—
Settlements —
(3 ) (3 ) —
(2 ) (2 )
Balance at September 30 $ 1
$ —
$ 1
$ 6
$ 3
$ 9


	For the three months ended March 31, 2023		For the three months ended March 31, 2022
	Private Placements
	(in millions)
Beginning balance at January 1	$	101	$	68
Total gains or losses:

Unrealized in other comprehensive income	1		(4)
Purchases	1		17
Sales	—		(1)

Transfer out	(4)		—
Balance at March 31	$	99	$	80

Financial Liabilities

Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, ~~including the current portion,~~ net of unamortized debt issuance costs, was ~~$4,780 million~~$11.2 billion at ~~September 30, 2017~~March 31, 2023 and ~~$3,792 million~~$10.0 billion at December 31, ~~2016.~~2022. The fair value of our senior notes debt ~~including the current portion,~~ was ~~$5,185 million~~$10.9 billion at ~~September 30, 2017~~March 31, 2023 and ~~$4,004 million~~$9.4 billion at December 31, ~~2016.~~2022. The fair value of our ~~long-term~~senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities.

~~Due to the short-term nature, carrying~~ Carrying value approximates fair value for our term loans and commercial paper borrowings. ~~There were outstanding~~The commercial paper borrowings ~~of $150~~were $426 million ~~as of September 30, 2017~~at March 31, 2023. The term loans and ~~$300 million as of~~commercial paper borrowings were $1.1 billion at December 31, ~~2016.~~2022.

Put and Call Options Measured at Fair Value

Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.

The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $318 million and $8 million, respectively, at March 31, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December 31, 2022.

The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)


	March 31, 2023		December 31, 2022
Annualized volatility	16.7% - 19.3%		16.7% - 20.8%
Credit spread	1.2% - 1.4%		1.3% - 1.5%
Revenue exit multiple	1.5x - 2.5x		1.5x - 2.5x
Weighted average cost of capital	12.0% - 13.0%		11.5% - 12.5%
Long term growth rate	3.0	%	3.0	%

The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.

Other Assets and Liabilities Measured at Fair Value

Certain assets and liabilities are measured at fair value on a ~~Nonrecurring Basis~~

non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we ~~completed the acquisition of certain~~acquired various health and wellness related businesses during ~~2017 and 2016.~~2023. The ~~values of~~ net ~~tangible~~ assets acquired and ~~the~~ resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The ~~majority of the~~net tangible assets ~~acquired~~including receivables and accrued liabilities ~~assumed~~ were recorded at their carrying ~~values as of the respective dates of acquisition, as their carrying values~~value which approximated their fair ~~values~~value due to their ~~short-term~~short term nature. The fair ~~values~~value of goodwill and other intangible assets ~~acquired in these acquisitions~~ were internally estimated based primarily ~~based~~ on the income approach. The income approach estimates fair value based on the present value of ~~the~~ cash ~~flows~~flow that the assets ~~are~~could be expected to generate in the future. We developed internal estimates for ~~the~~ expected cash flows ~~and discount rates used~~ in the present value ~~calculations.~~ calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.

As disclosed in Note 3, we completed the sale of Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of the Home Solutions reporting unit included within the CenterWell segment.

Other than the assets ~~acquired~~ and liabilities ~~assumed in these acquisitions,~~acquired during 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during ~~2017 or 2016.~~2023.

For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

6. MEDICARE PART D

We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or ~~CMS, as described further in Note 2 to the consolidated financial statements included in our 2016 Form 10-K.~~CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016.~~2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers.

September 30, 2017 December 31, 2016
Risk
Corridor
Settlement CMS
Subsidies/
Discounts Risk
Corridor
Settlement CMS
Subsidies/
Discounts
(in millions)
Other current assets $ 9
$ 1,058
$ 8
$ 1,001
Trade accounts payable and accrued expenses (118 ) (2,134 ) (158 ) (128 )
Net current (liability) asset (109 ) (1,076 ) (150 ) 873
Other long-term assets 3
—
—
—
Other long-term liabilities (180 ) —
—
—
Net long-term liability (177 ) —
—
—
Total net (liability) asset $ (286 ) $ (1,076 ) $ (150 ) $ 873

~~7. HEALTH CARE REFORM~~

~~The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (which we collectively~~ For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to as the Health Care Reform Law) established risk spreading premium stabilization programs effective January 1, 2014, including a permanent risk adjustment program and temporary risk corridor and reinsurance programs, which we collectively refer to as the 3Rs. The 3Rs are applicable to certain of our commercial medical insurance products as further discussed in Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our ~~2016~~2022 Form 10-K. Operating results for our Individual Commercial medical business compliant with the Health Care Reform Law have been challenged primarily due to unanticipated modifications in the program subsequent to the passing of the Health Care Reform Law, resulting in higher covered population morbidity and the ensuing enrollment and claims issues causing volatility in claims experience. We took a number of actions in 2015 to improve the profitability of our Individual Commercial medical business in 2016. These actions were subject to regulatory restrictions in certain geographies and included premium increases for the 2016 coverage year related generally to the first half of 2015 claims experience, the discontinuation of certain products as well as exit of certain markets for 2016, network improvements, enhancements to claims and clinical processes and administrative cost control. Despite these actions, the deterioration in the second half of 2015 claims experience together with 2016 open enrollment results indicating the retention of many high-utilizing members

~~Humana Inc.~~


	March 31, 2023				December 31, 2022
	Risk Corridor Settlement		CMS Subsidies/ Discounts		Risk Corridor Settlement		CMS Subsidies/ Discounts
	(in millions)
Other current assets	$	86	$	239	$	240	$	696
Trade accounts payable and accrued expenses	(147)		(3,805)		(166)		(1,236)
Net current (liability) asset	(61)		(3,566)		74		(540)
Other long-term assets	307		—		19		—
Other long-term liabilities	(93)		—		(78)		—
Net long-term asset (liability)	214		—		(59)		—
Total net asset (liability)	$	153	$	(3,566)	$	15	$	(540)

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

for 2016 resulted in a probable future loss. As a result of our then assessment of the profitability of our individual medical policies compliant with the Health Care Reform Law, in the fourth quarter of 2015, we recorded a provision for probable future losses (premium deficiency reserve, or PDR) for the 2016 coverage year of $176 million in benefits payable in our consolidated balance sheet with a corresponding increase in benefits expense in our consolidated statement of income. During the second quarter of 2016 we increased the premium deficiency reserve for the 2016 coverage year and recorded a change in estimate of $208 million with a corresponding increase in benefits expense in our condensed consolidated statement of income for the three months ended June 30, 2016.

On November 10, 2016, the U.S. Court of Federal Claims ruled in favor of the government in one of a series of cases filed by insurers, unrelated to us, against the U.S. Department of Health and Human Services, or HHS, to collect risk corridor payments, rejecting all of the insurer’s statutory, contract and Constitutional claims for payment. On November 18, 2016, HHS issued a memorandum indicating a significant funding shortfall for the 2015 coverage year, the second consecutive year of significant shortfalls. Given the successful challenge of the risk corridor provisions in court, Congressional inquiries into the funding of the risk corridor program, and significant funding shortfalls under the first two years of the program, during the fourth quarter of 2016 we wrote-off $583 million in risk corridor receivables outstanding as of September 30, 2016, including $415 million associated with the 2014 and 2015 coverage years. From inception of the risk corridor program through September 30, 2017, we collected approximately $39 million from CMS for risk corridor receivables associated with the 2014 coverage year funded by HHS in accordance with previous guidance, utilizing funds HHS collected from us and other carriers under the risk corridor program. On November 2, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, on behalf of our health plans seeking recovery from the federal government of approximately $611 million in payments under the risk corridor premium stabilization program established under Health Care Reform, for years 2014, 2015 and 2016.

On February 14, 2017, we announced we are exiting our Individual Commercial medical business commencing January 1, 2018. As discussed previously, we have worked over the past several years to address market and programmatic challenges in order to keep coverage options available wherever we could offer a viable product. This has included pursuing business changes, such as modifying networks, restructuring product offerings, reducing the company’s geographic footprint and increasing premiums. All of these actions were taken with the expectation that our Individual Commercial medical business would stabilize to the point where we could continue to participate in the program. However, based on our analysis of data associated with our healthcare exchange membership following the 2017 open enrollment period, we saw further signs of an unbalanced risk pool. Therefore, we decided that we cannot continue to offer this coverage and will exit this business commencing January 1, 2018.

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~The accompanying condensed consolidated balance sheets include the following amounts associated with the 3Rs at September 30, 2017 and December 31, 2016.~~

September 30, 2017 December 31, 2016
Risk Adjustment
Settlement Reinsurance
Recoverables Risk Adjustment
Settlement Reinsurance
Recoverables
(in millions)
Prior Coverage Years
Premiums receivable $ 127 $ —
$ 307 $ —
Other current assets — 44
— 260
Trade accounts payable and
accrued expenses — —
(117 ) —
Net current asset 127 44
190 260
Other long-term assets — —
6 —
Total prior coverage years' net
asset 127 44
196 260
Current Coverage Year
Premiums receivable 30 —
— —
Trade accounts payable and
accrued expenses (57 ) —
— —
Net current liability (27 ) —
— —
Other long-term assets 29 —
— —
Other long-term liabilities — —
— —
Net long-term asset 29 —
— —
Total 2017 coverage year net
asset 2 —
— —
Total net asset $ 129 $ 44
$ 196 $ 260

During the nine months ended September 30, 2017, we received $283 million for reinsurance recoverables and $176 million for risk adjustment and risk corridor settlements, and paid $152 million in risk adjustment charges, in each case associated with prior coverage years. During the nine months ended September 30, 2016, we received $471 million for reinsurance recoverables as well as $88 million for risk adjustment and risk corridor settlements, and paid $240 million in risk adjustment charges, in each case associated with prior coverage years.

To the extent certain provisions of the Health Care Reform Law are successfully challenged in court or there are changes in legislation or the application of legislation, there can be no guarantee that receivables established under the reinsurance or risk adjustment provisions of the Health Care Reform Law will ultimately be collected. Potential legislative changes, including activities to repeal or replace the Health Care Reform Law, creates uncertainty for our business, and we cannot predict when, or in what form, such legislative changes may occur.

The annual health insurance industry fee has been suspended for calendar year 2017, but is scheduled to resume in calendar year 2018. In September 2016, we paid the federal government $916 million for our portion of the annual health insurance industry fee attributed to calendar year 2016 in accordance with the Health Care Reform Law. This fee, fixed in amount by law and apportioned to insurance carriers based on market share, is not deductible for tax purposes. Each year on January 1, except for 2017, we record a liability for this fee in trade accounts payable and accrued expenses which we carry until the fee is paid. We record a corresponding deferred cost in other current assets in our condensed consolidated financial statements which is amortized ratably to expense over the calendar year. Amortization of the deferred cost was recorded in operating cost expense of approximately $231 million and $687 million for the three and nine months ended September 30, 2016, respectively, resulting from the amortization of the 2016 annual health insurance industry fee.

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

8.7. GOODWILL AND OTHER INTANGIBLE ASSETS

~~The carrying amount of goodwill for our reportable segments has been retrospectively adjusted to conform to the 2017 business segment reclassifications as discussed in Note 1. There was no impairment.~~ Changes in the carrying amount of goodwill for our reportable segments for the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2023 were as follows:


	Insurance		CenterWell		Total
	(in millions)
Balance at January 1, 2023	$	2,472	$	6,670	$	9,142
Acquisitions	106		72		178


Balance at March 31, 2023	$	2,578	$	6,742	$	9,320

Retail Group and Specialty Healthcare
Services Total
(in millions)
Balance at January 1, 2017 $ 1,059
$ 261
$ 1,952
$ 3,272
Acquisitions —
—
9
9
Balance at September 30, 2017 $ 1,059
$ 261
$ 1,961
$ 3,281

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016.~~2022:


		March 31, 2023						December 31, 2022
	Weighted Average Life	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
		($ in millions)
Other intangible assets:
Certificates of need	Indefinite	$	1,132	$	—	$	1,132	$	1,132	$	—	$	1,132
Medicare licenses	Indefinite	286		—		286		286		—		286
Customer contracts/ relationships	9.3 years	932		685		247		929		673		256
Trade names and technology	6.8 years	134		101		33		142		107		35
Provider contracts	11.6 years	73		63		10		73		63		10
Noncompetes and other	8.4 years	84		38		46		86		40		46

Total other intangible assets	9.1 years	$	2,641	$	887	$	1,754	$	2,648	$	883	$	1,765

September 30, 2017 December 31, 2016
Weighted
Average
Life Cost Accumulated
Amortization Net Cost Accumulated
Amortization Net
($ in millions)
Other intangible assets:
Customer contracts/
relationships 9.8 years $ 566
$ 388
$ 178
$ 566
$ 347
$ 219
Trade names and
technology 8.2 years 104
77
27
104
69
35
Provider contracts 14.1 years 51
33
18
51
29
22
Noncompetes and
other 8.1 years 33
29
4
32
28
4
Total other intangible
assets 9.8 years $ 754
$ 527
$ 227
$ 753
$ 473
$ 280

~~Amortization~~ For the three months ended March 31, 2023 and 2022, amortization expense for other intangible assets was approximately $18 million for the three months ended September 30, 2017 and 2016. For the nine months ended September 30, 2017 and 2016, amortization expense for other intangible assets was approximately $54 million and $59 million, respectively.million. The following table presents our estimate of amortization expense remaining for ~~2017~~2023 and each of the five next succeeding ~~years:~~years at March 31, 2023:


	(in millions)
For the years ending December 31,
2023	$	47
2024	56
2025	54
2026	41
2027	32
2028	27

For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

(in millions)
For the years ending December 31,
2017 $ 71
2018 63
2019 52
2020 48
2021 14
2022 11

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

9.8. BENEFITS PAYABLE

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable ~~excluding military services,~~ was as follows for the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2023 and ~~2016:~~2022:


	For the three months ended March 31,
	2023		2022
	(in millions)
Balances, beginning of period	$	9,264	$	8,289

Incurred related to:
Current year	22,380		19,985
Prior years	(522)		(360)
Total incurred	21,858		19,625
Paid related to:
Current year	(14,203)		(12,284)
Prior years	(6,901)		(6,252)
Total paid	(21,104)		(18,536)
Balances, end of period	$	10,018	$	9,378

For the nine months ended September 30,
2017 2016
(in millions)
Balances, beginning of period $ 4,563
$ 4,976
Less: Premium deficiency reserve —
(176 )
Less: Reinsurance recoverables (76 ) (85 )
Balances, beginning of period, net 4,487
4,715
Incurred related to:
Current year 33,318
34,340
Prior years (430 ) (525 )
Total incurred 32,888
33,815
Paid related to:
Current year (28,741 ) (29,768 )
Prior years (3,745 ) (3,996 )
Total paid (32,486 ) (33,764 )
Premium deficiency reserve —
206
Reinsurance recoverable 70
77
Balances, end of period $ 4,959
$ 5,049
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At March 31, 2023, benefits payable included IBNR of approximately $6.3 billion, primarily associated with claims incurred in 2023.

Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).

Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

~~Benefits expense excluded from the previous table was as follows for the nine months ended September 30, 2017 and 2016.~~

For the nine months ended September 30,
2017 2016
(in millions)
Premium deficiency reserve - Individual Commercial $ —
$ 30
Military services —
7
Future policy benefits:
Individual Commercial (67 ) (82 )
Other Businesses 36
36
Total future policy benefits (31 ) (46 )
Total $ (31 ) $ (9 )

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

~~Military services benefits expense in the tables above reflect expenses associated with our contracts with the Veterans Administration.~~

~~Incurred and Paid Claims Development~~

The following discussion provides information about incurred and paid claims development for our Retail, Group and Specialty, and Individual Commercial segments as of September 30, 2017 and 2016, net of reinsurance and the total of IBNR included within the net incurred claims amounts.

~~Retail Segment~~

~~Activity in benefits payable for our Retail segment was as follows for the nine months ended September 30, 2017 and 2016:~~

For the nine months ended September 30,
2017 2016
(in millions)
Balances, beginning of period $ 3,507
$ 3,600
Less: Reinsurance recoverables (76 ) (85 )
Balances, beginning of period, net 3,431
3,515
Incurred related to:
Current year 29,356
28,369
Prior years (339 ) (378 )
Total incurred 29,017
27,991
Paid related to:
Current year (25,460 ) (24,822 )
Prior years (2,822 ) (2,990 )
Total paid (28,282 ) (27,812 )
Reinsurance recoverable 70
77
Balances, end of period $ 4,236
$ 3,771

~~At September 30, 2017, benefits payable for our Retail segment included IBNR of approximately $2.7 billion, primarily associated with claims incurred in 2017.~~

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~Group and Specialty Segment~~

~~Activity in benefits payable for our Group and Specialty segment, excluding military services, was as follows for the nine months ended September 30, 2017 and 2016:~~

For the nine months ended September 30,
2017 2016
(in millions)
Balances, beginning of period $ 578
$ 616
Incurred related to:
Current year 3,996
3,918
Prior years (44 ) (42 )
Total incurred 3,952
3,876
Paid related to:
Current year (3,452 ) (3,337 )
Prior years (517 ) (557 )
Total paid (3,969 ) (3,894 )
Balances, end of period $ 561
$ 598

~~At September 30, 2017, benefits payable for our Group and Specialty segment included IBNR of approximately $490 million, primarily associated with claims incurred in 2017.~~

~~Individual Commercial Segment~~

~~Activity in benefits payable for our Individual Commercial segment was as follows for the nine months ended September 30, 2017 and 2016:~~

For the nine months ended September 30,
2017 2016
(in millions)
Balances, beginning of period $ 454
$ 740
Less: Premium deficiency reserve —
(176 )
Balances, beginning of period, net 454
564
Incurred related to:
Current year 502
2,694
Prior years (46 ) (104 )
Total incurred 456
2,590
Paid related to:
Current year (393 ) (2,273 )
Prior years (383 ) (430 )
Total paid (776 ) (2,703 )
Premium deficiency reserve —
206
Balance, end of period $ 134
$ 657

~~At September 30, 2017, benefits payable for our Individual Commercial segment included IBNR of approximately $120 million, primarily associated with claims incurred in 2017.~~

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~Reconciliation to Consolidated~~

~~The reconciliation of the net incurred and paid claims development tables to benefits payable in the consolidated~~

~~statement of financial position is as follows:~~

Reconciliation of the Disclosure of Incurred and Paid Claims Development to Benefits Payable, net of reinsurance

September 30,
2017
Net outstanding liabilities
Retail $ 4,166
Group and Specialty 561
Individual Commercial 134
Other Businesses 28
    Benefits payable, net of reinsurance 4,889

Reinsurance recoverable on unpaid claims
Retail 70
     Total reinsurance recoverable on unpaid claims 70

     Total benefits payable, gross $ 4,959

~~10.~~9. EARNINGS PER COMMON SHARE COMPUTATION

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016:~~2022:


	Three months ended March 31,
	2023		2022
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	1,239	$	930
Weighted average outstanding shares of common stock used to compute basic earnings per common share	125,005		126,938
Dilutive effect of:
Employee stock options	34		40
Restricted stock	525		496
Shares used to compute diluted earnings per common share	125,564		127,474
Basic earnings per common share	$	9.91	$	7.32
Diluted earnings per common share	$	9.87	$	7.29
Number of antidilutive stock options and restricted stock excluded from computation	538		626

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Three months ended September 30, Nine months ended September 30,
2017 2016 2017 2016
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders $ 499
$ 450
$ 2,264
$ 1,015
Weighted average outstanding shares of common stock
used to compute basic earnings per common share 144,215
149,417
145,546
149,321
Dilutive effect of:
Employee stock options 165
210
174
216
Restricted stock 980
1,277
902
1,332
Shares used to compute diluted earnings per common share 145,360
150,904
146,622
150,869
Basic earnings per common share $ 3.46
$ 3.01
$ 15.56
$ 6.80
Diluted earnings per common share $ 3.44
$ 2.98
$ 15.44
$ 6.73
Number of antidilutive stock options and restricted stock
excluded from computation 399
658
595
873

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~11.~~10. STOCKHOLDERS’ EQUITY

Dividends

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, ~~in 2016 and 2017~~during 2023 under our Board approved quarterly cash dividend policy:

Record
Date

Payment
Date

Amount
per Share

Total
Amount

(in millions)

12/30/2022

1/27/2023

0.7900

Record
Date Payment
Date Amount
per Share Total
Amount
(in millions)
2016 payments
12/30/2015 1/29/2016 $ 0.29
$ 43
3/31/2016 4/29/2016 $ 0.29
$ 43
6/30/2016 7/29/2016 $ 0.29
$ 43
10/13/2016 10/28/2016 $ 0.29
$ 43
2017 payments
1/12/2017 1/27/2017 $ 0.29
$ 43
3/31/2017 4/28/2017 $ 0.40
$ 58
6/30/2017 7/31/2017 $ 0.40
$ 58
9/29/2017 10/27/2017 $ 0.40
$ 57

~~On November 2, 2017,~~In February 2023, the Board declared a cash dividend of ~~$0.40~~$0.885 per share payable on ~~January 26, 2018,~~April 28, 2023 to stockholders of record on ~~December 29, 2017.~~March 31, 2023. In April 2023, the Board declared a cash dividend of $0.885 per share payable on July 28, 2023 to stockholders of record as of the close of business on June 30, 2023. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

~~On February 14, 2017, our~~Our Board of Directors ~~replaced a previous share repurchase authorization of up to $2 billion, of which $1.04 billion remained unused, with a new authorization for repurchases of up to $2.25 billion~~may authorize the purchase of our common ~~shares expiring on December 31, 2017, exclusive of shares repurchased in connection with employee~~ stock ~~plans.~~shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.

~~On February 16, 2017, we entered into an accelerated share repurchase agreement, or ASR Agreement, with Goldman, Sachs & Co. LLC, or Goldman Sachs, to repurchase $1.5 billion~~

Table of our common stock as part of the $2.25 billion share repurchase program referred to above. Under the ASR Agreement, on February 22, 2017, we made a payment of $1.5 billion to Goldman Sachs from available cash on hand and received an initial delivery of 5.83 million shares of our common stock from Goldman Sachs based on the then current market price of Humana common stock. The payment to Goldman Sachs was recorded as a reduction to stockholders’ equity, consisting of a $1.2 billion increase in treasury stock, which reflected the value of the initial 5.83 million shares received upon initial settlement, and a $300 million decrease in capital in excess of par value, which reflected the value of stock held back by Goldman Sachs pending final settlement of the ASR Agreement. Upon settlement of the ASR on August 28, 2017, we received an additional 0.84 million shares as determined by the average daily volume weighted-average share price of our common stock during the term of the ASR Agreement of $224.81, bringing the total shares received under this program to 6.67 million. In addition, upon settlement we reclassified the $300 million value of stock initially held back by Goldman Sachs from capital in excess of par value to treasury stock.Contents

~~Our remaining repurchase authorization was approximately $239 million as of November 3, 2017.~~

In connection with employee stock plans, we acquired 0.37 million common shares for $79 million and 0.45 million common shares for $75 million during the nine months ended September 30, 2017 and 2016, respectively.

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

~~Treasury Stock Reissuance~~

~~We reissued 1.40~~On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. During the three months ended March 31, 2023, we repurchased 0.1 million shares in open market transactions for $67 million at an average price of ~~treasury~~$495.68 under the current share repurchase authorization. During the three months ended March 31, 2022 we did not repurchase shares in open market transactions.

Our remaining repurchase authorization was $2.8 billion as of April 25, 2023.

In connection with employee stock plans, we acquired 0.05 million common shares for $27 million and 0.06 million common shares for $24 million during the ~~nine~~three months ended ~~September 30, 2017 at a cost of $99 million associated with restricted stock unit vestings~~March 31, 2023 and ~~option exercises.~~2022, respectively.

~~Accumulated Other Comprehensive Income~~

~~Accumulated other comprehensive income included net unrealized gains, net of tax, on~~For additional information regarding our investment securities of $107 million at September 30, 2017 and net unrealized losses, net of tax, of $17 million at December 31, 2016. In addition, accumulated other comprehensive income included $95 million, net of tax, at September 30, 2017 and $49 million, net of tax, at December 31, 2016 for an additional liability that would exist on our closed block of long-term care insurance policies if unrealized gains on the sale of the investments backing such products had been realized and the proceeds reinvested at then current yields. Referstockholders' equity, refer to Note 1816 to the ~~consolidated financial statements~~audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our ~~2016~~2022 Form ~~10-K for further discussion of our long-term care insurance policies.~~10-K.

~~12.~~

11. INCOME TAXES

The effective income tax rate was ~~37.5%~~22.5% and 23.5% for the three months ended September 30, 2017, compared to 50.1% for the three months ended September 30, 2016 and was 35.9% for the nine months ended September 30, 2017, compared to 50.2% for the nine months ended September 30, 2016, primarily due to the 2017 temporary suspension of the non-deductible health insurance industry fee as well as previously non-deductible transaction costs that, as a result of termination of the Merger Agreement, became deductible for tax purposes and were recorded as such in the three months ended March 31, ~~2017.~~ 2023 and 2022, respectively. The year-over-year decrease in the effective income tax rate is primarily due to the recognition of a non-taxable gain in the 2023 quarter.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

~~13.~~12. DEBT

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016~~:2022:


	March 31, 2023		December 31, 2022
	(in millions)
Short-term debt:
Commercial paper	$	426	$	595

Senior notes:
$1.5 billion, 0.650% due August 3, 2023	1,441		1,497
Total senior notes	1,441		1,497
Total short-term debt	$	1,867	$	2,092
Long-term debt:
Senior notes:
$600 million, 3.850% due October 1, 2024	$	595	$	599
$600 million, 4.500% due April 1, 2025	597		597
$500 million, 5.700% due March 13, 2026	497		—
$750 million, 1.350% due February 3, 2027	745		745
$600 million, 3.950% due March 15, 2027	597		597
$500 million, 5.750% due March 1, 2028	494		494
$750 million, 3.700% due March 23, 2029	743		743
$500 million, 3.125% due August 15, 2029	496		496
$500 million, 4.875% due April 1, 2030	496		495
$750 million, 2.150% due February 3, 2032	743		743
$750 million, 5.880% due March 1, 2033	740		739
$250 million, 8.150% due June 15, 2038	261		261
$400 million, 4.625% due December 1, 2042	396		396
$750 million, 4.950% due October 1, 2044	740		740
$400 million, 4.800% due March 15, 2047	396		396
$500 million, 3.950% due August 15, 2049	493		493
$750 million, 5.500% due March 15, 2053	714		—
Total senior notes	9,743		8,534
Term loans:
Delayed draw term loan, due May 28, 2024	—		500
Total term loans	—		500
Total long-term debt	$	9,743	$	9,034

September 30, 2017 December 31, 2016
(in millions)
Short-term:
Commercial paper $ 150
$ 300
$500 million, 7.20% Senior notes due June 15, 2018 501
—
  $300 million, 6.30% Senior notes due August 1, 2018 302
—
Total short-term debt 953
300

Long-term:
Senior notes:
  $500 million, 7.20% due June 15, 2018 —
501
  $300 million, 6.30% due August 1, 2018 —
304
  $400 million, 2.625% due October 1, 2019 399
398
  $600 million, 3.15% due December 1, 2022 596
595
  $600 million, 3.85% due October 1, 2024 595
595
  $600 million, 3.95% due March 15, 2027 594
—
  $250 million, 8.15% due June 15, 2038 263
264
  $400 million, 4.625% due December 1, 2042 396
396
  $750 million, 4.95% due October 1, 2044 739
739
  $400 million, 4.80% due March 15, 2047 395
—
     Total long-term debt 3,977
3,792

Total debt $ 4,930
$ 4,092

Senior Notes

In March ~~2017,~~2023, we issued ~~$600~~$500 million of ~~3.95%~~5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, ~~2027 and $400 million of 4.80% senior notes due March 15, 2047.~~2053. Our net proceeds, reduced for the underwriters' ~~discount~~discounts and ~~commission and offering expenses~~commissions paid, ~~as of March 31, 2017,~~ were ~~$991 million.~~$1.2 billion. We ~~intend to use~~used the net proceeds ~~from these issuances~~to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate ~~purposes.~~purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

~~Our~~In March 2023, we entered into a Rule 10b5-1 Repurchase Plan, or the Plan, to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes ~~which are unsecured, may be redeemed at~~maturing in August 2023 and our ~~option at any time at 100%~~$600 million

Table of the principal amount plus accrued interest and a specified make-whole amount. The 7.20% and 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, each series of our senior notes (other than the 6.30% senior notes) contain a change of control provision that may require us to purchase the notes under certain circumstances.Contents

Prior to 2009, we were parties to interest-rate swap agreements that exchanged the fixed interest rate under our senior notes for a variable interest rate based on LIBOR. As a result, the carrying value of the senior notes was adjusted to reflect changes in value caused by an increase or decrease in interest rates. During 2008, we terminated all of our swap agreements. The cumulative adjustment to the carrying value of our senior notes was $103 million as of the termination date which is being amortized as a reduction to interest expense over the remaining term of the senior notes. The unamortized carrying value adjustment was $19 million as of ~~September 30, 2017~~ ~~and $23 million as of~~ ~~December 31, 2016~~.

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

aggregate principal amount of 3.850% senior notes maturing in October 2024 during the Plan period beginning on March 13, 2023 and ending on June 15, 2023. During the three months ended March 31, 2023, we repurchased $61 million aggregate principal amount, for cash totaling approximately $60 million.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Revolving Credit ~~Agreement~~Agreements

~~In May 2017 we amended and restated our previous 5-year $1.0 billion unsecured revolving~~Our credit agreement expiring July 2018 with a 5-year $2.0 billion unsecured revolving credit agreement which expires May 2022. Under the credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The LIBOR spread, currently ~~110.0~~ ~~basis points, varies depending on our credit ratings ranging from 91.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently~~ ~~15.0~~ basis points, may fluctuate between 9.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.

The terms of the credit agreement include standard provisions related to conditions of borrowing, including a customary material adverse effect clause which could limit our ability to borrow additional funds. In addition, the credit agreement containsagreements contain customary restrictive covenants and a financial ~~covenants~~covenant regarding maximum debt to capitalization of 60%, as well as customary events of ~~default, including financial covenants regarding the maintenance of a minimum level of net worth of~~ ~~$9.1 billion~~ at ~~September 30, 2017~~ ~~and a maximum leverage ratio of 3.0:1.~~default. We are in compliance with ~~the~~this financial ~~covenants,~~covenant, with actual ~~net worth~~debt to capitalization of ~~$11.2 billion and an actual leverage ratio of 1.1:1~~41.1% as measured in accordance with the revolving credit ~~agreement~~agreements as of ~~September 30, 2017~~. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the credit agreement to a maximum of $2.5 billion, through a $500.0 million incremental loan facility.March 31, 2023.

At ~~September 30, 2017~~,March 31, 2023, we had no borrowings and noapproximately $39 million of letters of credit outstanding under the revolving credit ~~agreement.~~agreements, including those of KAH. Accordingly, as of ~~September 30, 2017~~,March 31, 2023, we had ~~$2.0~~$2.4 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted ~~$500~~$750 million of incremental loan ~~facility under the credit agreement)~~facilities), none of which would be restricted by our financial covenant compliance requirement. ~~We have other customary, arms-length relationships, including financial advisory and banking, with some parties~~

For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the ~~credit agreement.~~audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Commercial Paper

~~We previously entered into a~~Under our commercial paper program ~~pursuant to which~~ we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers. On June 15, 2017, we increased the size of the commercial paper program to permit the issuance of the commercial notes with the aggregate face or principal amount outstanding under the programdealers at any ~~time not to exceed $2 billion.~~time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2023 was ~~$500 million. There were~~$626 million, with $426 million outstanding ~~borrowings of $150~~at March 31, 2023 compared to $595 million ~~at September 30, 2017 and $300 million~~outstanding at December 31, ~~2016.~~ 2022. The outstanding commercial paper at March 31, 2023 had a weighted average annual interest rate of 5.45%.

For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

~~14.~~Other Short-term Borrowings

We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At March 31, 2023 we had no outstanding short-term FHLB borrowings.

13. COMMITMENTS, GUARANTEES AND CONTINGENCIES

Government Contracts

Our Medicare products, which accounted for approximately ~~78%~~84% of our total premiums and services revenue for the ~~nine~~three months ended ~~September 30, 2017,~~March 31, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for ~~2018,~~2023, and all of our product offerings filed with CMS for ~~2018~~2023 have been approved.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, ~~(BBA)~~or BBA, and the Benefits Improvement and Protection Act of 2000, ~~(BIPA),~~or BIPA, generally pays more

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to ~~reflect the~~account for certain demographic characteristics and health status of our enrolled ~~membership.~~members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information ~~from hospital inpatient, hospital outpatient, and physician providers~~ to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. ~~These compliance efforts include the internal contract level audits described in more detail below.~~

CMS ~~is phasing-in~~and the process of calculating risk scores using diagnoses data from the Risk Adjustment Processing System, or RAPS, to diagnoses data from the Encounter Data System, or EDS. The RAPS process requires MA plans to apply a filter logic based on CMS guidelines and only submit claims that satisfy those guidelines. For submissions through EDS, CMS requires MA plans to submit all the encounter data and CMS will apply the risk adjustment filtering logic to determine the risk scores. For 2016, 10%Office of the ~~risk score was calculated from claims data submitted through EDS, increasing to 25%~~Inspector General of the risk score calculated from claims data through EDS for 2017. In April 2017, CMS revised the pace of the phase-in. For 2018, 15% of the risk score will be calculated from claims data submitted through EDS. The phase-in from RAPS to EDS could result in different risk scores from each dataset as a result of plan processing issues, CMS processing issues,Health and Human Services, or ~~filtering logic differences between RAPS and EDS, and could have a material adverse effect on our results of operations, financial position, or cash flows.~~

~~CMS is continuing to~~HHS-OIG, perform audits of various companies’ ~~selected MA contracts related to this~~ risk adjustment diagnosis ~~data.~~data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices ~~which~~that influence the calculation of health status-related premium payments to MA plans.

In 2012, CMS released a “Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits.” The payment error calculation methodology provides that, in calculating the economic impact of audit results for an MA ~~contract, if any,~~contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.

In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit ~~sample will be~~methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the ~~entire MA contract after~~RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a ~~comparison~~specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”

Humana is considering its legal options with respect to CMS’s changed position on the FFS Adjuster and seeking clarity regarding our compliance obligations in light of the ~~audit results~~Final RADV Rule. We believe that the Final RADV Rule fails to ~~a similar audit~~address adequately the statutory requirement of ~~Medicare~~actuarial equivalence. Further, Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS ~~(we refer to the process of accounting for errors~~Adjuster in ~~FFS claims as the "FFS Adjuster"). This comparison of~~any RADV audit ~~results~~that CMS intends to extrapolate. We expect CMS to apply the ~~FFS error rate is necessary to determine the economic impact, if any, of~~Final RADV audit results because the government used the Medicare FFS program data set, including any attendant errors that are present in that data set, to estimate the costs of various health status conditions and to set the resulting adjustments to MA plans’ payment rates. CMS already makes other adjustments to payment rates based on a comparison of coding pattern differences between MA plans and Medicare FFS data (such as for frequency of coding for certain diagnoses in MA plan data versus the Medicare FFS program dataset).

~~The final RADV extrapolation methodology,~~Rule, including the first application of extrapolated audit results to determine audit settlements ~~is expected~~without a FFS Adjuster, to ~~be applied to~~CMS and HHS-OIG RADV ~~contract level~~ audits conducted for ~~contract year 2011~~PY 2018 and subsequent years. ~~CMS is currently conducting~~The Final RADV ~~contract level audits for contract years 2011, 2012, and 2013 in which two, five and five~~Rule, including the lack of ~~our Medicare Advantage plans are being audited, respectively. Per CMS guidance, selected MA contracts will be notified~~

Table of ~~an audit at some point after the close of the final reconciliation for the payment year being audited.~~Contents

Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. We perform internal contract level audits based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits is an audit of our Private Fee-For-

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

~~Service business which we used to represent~~ a ~~proxy of the~~ FFS Adjuster, ~~which has not yet been released. We based our accrual of estimated audit settlements for each contract year on the results of these internal contract level audits~~ and ~~update our estimates as each audit is completed. Estimates derived from these results were not material to our results of operations, financial position,~~any related regulatory, industry or cash flows. We report the results of these internal contract level audits to CMS, including identified overpayments, if any. However, as indicated, we are awaiting additional guidance from CMS regarding the FFS Adjuster. Accordingly, we cannot determine whether such RADV audits willcompany reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, ~~CMS' comments~~as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in ~~formalized guidance regarding “overpayments” to MA plans appear to be inconsistent~~connection with ~~CMS' prior RADV audit guidance.~~the risk adjustment model. These ~~statements, contained~~reviews may also result in the ~~preamble~~identification of errors and the submission of corrections to ~~CMS’ final rule release regarding Medicare Advantage~~CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.

As we explore our legal options and ~~Part D prescription drug benefit program regulations for Contract Year 2015, appear~~compliance obligations, we remain committed to ~~equate each Medicare Advantage risk adjustment data error with an “overpayment” without reconciliation to the principles underlying the FFS Adjuster referenced above. We will continue to work with~~working alongside CMS to ~~ensure~~promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

~~At September 30, 2017, our military services~~Our state-based Medicaid business, which accounted for approximately ~~0.7%~~7% of our total premiums and services revenue for the ~~nine~~three months ended ~~September 30, 2017,~~March 31, 2023 primarily consisted of ~~the TRICARE South Region contract. The current 5-year South Region contract, which was set to expire on~~serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.

At March 31, 2017, is subject to annual renewals on April 1 of each year during its term at the government’s option, including an option to extend for a sixth year through March 31, 2018. On March 2, 2017, we received notice that the Defense Health Agency, or DHA, had exercised its option to extend the TRICARE South Region contract for that sixth year. On July 21, 2016, we were notified by the DHA that we were awarded the contract for the new TRICARE East Region,2023, our Military business, which is a consolidation of the former North and South Regions, with delivery of health care services expected to commence on October 1, 2017. On March 30, 2017, we received notice that the DHA is moving the date upon which delivery of health care services is expected to commence under the new TRICARE East Region contract from October 1, 2017 to January 1, 2018. We expect the sixth option period under the current TRICARE South Region contract would be terminated in the event that delivery of health care services under the new TRICARE East Region contract commences prior to March 31, 2018.

~~Our state-based Medicaid business~~ accounted for approximately 5%1% of our total premiums and services revenue for the ~~nine~~three months ended ~~September 30, 2017. In addition~~March 31, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprising 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to our state-based Temporary Assistance for Needy Families, or TANF, Medicaid contracts in Florida and Kentucky, we have contracts in Florida for Long Term Support Services (LTSS), in Illinois and Virginia for stand-alone dual eligible demonstration programs serving individuals dually eligible for both the federal Medicare program and the applicable state-based Medicaid program, as well as an Integrated Care Program, or ICP, Medicaid contract in Illinois. Our Integrated Care Program Medicaid contract in Illinois, and the Virginia stand-alone dual eligible demonstration program both will terminate atexpire on December 31, ~~2017.~~2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2023, unless further extended.

In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the TRICARE East Region by the Defense Health Agency of the DoD. The contract is expected to go into effect in 2024. Until then the T2017 contract remains in place. Under the terms of the award, our service area covers approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.

The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by ~~comparison of~~regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and ~~a requirement~~require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

Legal Proceedings and Certain Regulatory Matters

On January 6, 2012, the Civil Division of the United States Attorney’s Office for the Southern District of Florida advised us that it is seeking documents and information from us and several of our affiliates relating to several matters including the coding of medical claims by one or more South Florida medical providers, and loans to physician practices. On May 1, 2014, the U.S. Attorney's Office filed a Notice of Non-Intervention in connection with a civil qui tam suit related to one of these matters captioned ~~United States of America ex rel. Olivia Graves v. Plaza Medical Centers, et al.~~, and the Court ordered the complaint unsealed. Subsequently, the individual plaintiff amended the complaint and served the Company, opting to continue to pursue the action. As of November 7, 2017, all parties to the lawsuit and the United States have executed a settlement agreement to settle the plaintiff’s claims for damages and penalties, with Humana paying an amount that is not material to our results of operations. The parties are awaiting the court’s dismissal of the case.

As previously disclosed, the Civil Division of the United States Department of Justice ~~had~~ provided us with an information request ~~separate from but related to the Plaza Medical matter,~~in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, ~~including the providers identified in the Plaza Medical matter,~~ as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We ~~continue to cooperate~~cooperated with the Department of Justice, and ~~voluntarily respond to the information requests~~we have not heard from the Department of Justice ~~and the U.S. Attorney’s Office. These matters are expected to result in additional qui tam litigation.~~on this matter since 2020.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana, Inc., in United States District Court, Central District of California, Western Division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part ~~D, as compared to required benefit levels under applicable bid rules.~~D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator ~~can~~could proceed, following notice from the U.S. Government that it iswas not intervening at ~~this~~that time. On January 29, 2018, the suit was transferred to the United States District Court, Western District of Kentucky, Louisville Division. We have substantially completed discovery with the relator who has pursued the matter on behalf of the United States following its unsealing. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial ~~best principles,~~standards of practice, and ~~we intend~~continue to vigorously defend against these allegations.

On November 2, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, on behalf of our health plans seeking recovery from the federal government of approximately $611 million in payments under the risk corridor premium stabilization program established under Health Care Reform, for years 2014, 2015 and 2016. We have not recognized revenue, nor have we recorded a receivable, for any amount due from the federal government for unpaid risk corridor payments as of September 30, 2017. We have fully recognized all liabilities due to the federal government that we have incurred under the risk corridor program, and have paid all amounts due to the federal government as required. There is no assurance that we will prevail in the lawsuit.

Other Lawsuits and Regulatory Matters

Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, ~~and~~ sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. For example, a number of hospitals and other providers have asserted that, under their network provider contracts, we are not entitled to reduce Medicare Advantage payments to these providers in connection with changes in Medicare payment systems and in accordance with the Balanced Budget and Emergency Deficit Control Act of 1985, as amended (commonly referred to as “sequestration”). Those challenges have led and could lead to arbitration demands or other litigation. Also, underUnder state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do. Penn Treaty is a financially distressed unaffiliated long-term care insurance company. On March 1, 2017, a court ordered the liquidation of Penn Treaty which triggered assessments from state guaranty associations that resulted in our recording a $54 million estimate in operating costs in the three months ended March 31, 2017.

As a government contractor, we may also be subject to false claims litigation, such as qui tam ~~litigation~~lawsuits brought by individuals who seek to sue

on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the ~~lawsuit is unsealed, and the~~ individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of ~~non-performance~~nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.

A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.

The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

~~15.~~

14. SEGMENT INFORMATION

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

~~segment. As a result of this realignment, our reportable segments now include Retail, Group and Specialty,~~ Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and ~~Individual Commercial.~~ home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization.Prior period segment financial information has been recast to conform to the ~~2017~~2023 presentation.

~~We manage our business with four~~Our two reportable ~~segments: Retail, Group~~segments, Insurance and Specialty, Healthcare Services and Individual Commercial. In addition, the Other Businesses category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles. These segmentsCenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

The ~~Retail~~Insurance segment consists of Medicare benefits, marketed to individuals or directly via group ~~accounts. In addition, the Retail segment also includes~~Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. ~~The Group and Specialty~~This segment ~~consists~~also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health ~~and voluntary insurance~~ benefits, ~~and financial protection products,~~ as well as administrative services only, or ~~ASO products.~~ASO. In addition, our ~~Group and Specialty~~Insurance segment includes ~~military services~~our Military business, primarily our ~~TRICARE South~~T-2017 East Region ~~contract. The Healthcare Services segment includes services offered to our health plan members~~contract, as well as ~~to third parties, including~~the operations of our PBM business.

The CenterWell segment includes our pharmacy, ~~solutions,~~ provider services, and ~~clinical~~home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care ~~service,~~centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services ~~and capabilities~~may lead to ~~promote wellness and advance population health. The Individual Commercial segment consists of our individual commercial fully-insured medical~~lower utilization associated with improved member health insurance benefits. We report under the category of Other Businesses those businesses that do not align with the reportable segments described above, primarily our closed-block long-term care insurance policies.and/or lower drug costs.

Our ~~Healthcare Services~~CenterWell intersegment revenues primarily relate to ~~managing prescription drug coverage for members of our other segments through Humana Pharmacy Solutions~~^®~~, or HPS, and includes~~ the operations of ~~Humana~~CenterWell Pharmacy ~~Inc., our mail~~(our mail- order pharmacy ~~business. These revenues consist of the prescription price (ingredient cost plus dispensing fee)~~business), including the portion to be settled with the member (co-share) or with the government (subsidies), plus any associated administrative fees. Services revenues related to the distribution of prescriptions by third partyCenterWell Specialty Pharmacy, and retail pharmacies in our networks are recognized when the claim is processed and product revenues from dispensing prescriptions from our mail order pharmacies are recorded when the prescription or product is shipped. Our pharmacy operations, which are responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims, act as a principal in the arrangement on behalfjointly located within CenterWell Senior Primary Care clinics.

Table of members in our other segments. As principal, our Healthcare Services segment reports revenues on a gross basis, including co-share amounts from members collected by third party retail pharmacies at the point of service.Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

In addition, our ~~Healthcare Services~~CenterWell intersegment revenues include revenues earned by certain owned providers derived from ~~risk-based and non-risk-based managed care agreements~~certain value-based arrangements with our health plans. Under ~~risk based~~these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a ~~monthly capitated fee~~premium that varies depending on the demographics and health status of the member, for each member assigned to these owned providers by our health plans. The owned provider assumes the economic risk of funding the assigned members’ healthcare services. Under non risk-based agreements, our health plans retain the economic risk of funding the assigned members' healthcare services. Our Healthcare Services segment reports provider services revenues associated with risk-based agreementsis typically paid on a ~~gross basis, whereby capitation fee revenue is~~per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which ~~the assigned members~~we are ~~entitled~~obligated to ~~receive healthcare services. Provider~~provide integrated health care services ~~revenues associated with non-risk-based agreements are presented~~to our members. Fee-for-service revenue is recognized at agreed upon rates, net of ~~associated healthcare costs.~~contractual allowances, as the performance obligation is completed on the date of service.

We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of ~~$3.6~~$4.0 billion and $4.0 billion for the three months ended ~~September 30, 2017~~March 31, 2023 and ~~2016. For the nine months ended September 30, 2017 and 2016 these amounts were $9.8 billion and $9.7 billion,~~2022, respectively. In addition, depreciation and amortization expense associated with certain businesses ~~in our Healthcare Services segment~~ delivering benefits to our members, primarily associated with our

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

provider services and pharmacy operations, are included with benefits expense. The amount of this expense was ~~$26~~$33 million and ~~$31~~$30 million for the three months ended ~~September 30, 2017~~March 31, 2023 and ~~2016, respectively. For the nine months ended September 30, 2017 and 2016, the amount of this expense was $79 million and $85 million,~~2022, respectively.

Other than those described previously, the accounting policies of each segment are the ~~same and are described in~~same. For additional information regarding our accounting policies refer to Note 2 to the ~~consolidated financial statements~~audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our ~~2016~~2022 Form 10-K. Transactions between reportable segments primarily consist of sales of services rendered by our ~~Healthcare Services~~CenterWell segment, primarily pharmacy, provider, and ~~clinical care~~home services, to our ~~Retail, Group and Specialty, and Individual Commercial~~Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

Our segment results were as follows for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016:~~2022:


	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended March 31, 2023	(in millions)
External revenues
Premiums:
Individual Medicare Advantage	$	19,809	$	—	$	—	$	19,809
Group Medicare Advantage	1,765		—		—		1,765
Medicare stand-alone PDP	616		—		—		616
Total Medicare	22,190		—		—		22,190
Commercial fully-insured	1,018		—		—		1,018
Specialty benefits	254		—		—		254
Medicare Supplement	179		—		—		179
Medicaid and other	1,909		—		—		1,909
Total premiums	25,550		—		—		25,550
Services revenue:


Home solutions	—		314		—		314
Provider services	—		201		—		201
Commercial ASO	71		—		—		71
Military and other	171		—		—		171
Pharmacy solutions	—		242		—		242
Total services revenue	242		757		—		999
Total external revenues	25,792		757		—		26,549
Intersegment revenues
Services	14		1,133		(1,147)		—
Products	—		2,615		(2,615)		—
Total intersegment revenues	14		3,748		(3,762)		—
Investment income	97		—		96		193
Total revenues	25,903		4,505		(3,666)		26,742
Operating expenses:
Benefits	21,993		—		(135)		21,858
Operating costs	2,418		4,126		(3,565)		2,979

Depreciation and amortization	165		49		(28)		186
Total operating expenses	24,576		4,175		(3,728)		25,023
Income from operations	1,327		330		62		1,719

Interest expense	—		—		113		113
Other income, net	—		—		(8)		(8)
Income (loss) before income taxes and equity in net losses	1,327		330		(43)		1,614
Equity in net losses	(3)		(14)		—		(17)
Segment earnings (loss)	$	1,324	$	316	$	(43)	$	1,597
Net loss attributable to noncontrolling interests	1		—		—		1
Segment earnings (loss) attributable to Humana	$	1,325	$	316	$	(43)	$	1,598

Retail Group and Specialty Healthcare
Services Individual Commercial Other
Businesses Eliminations/
Corporate Consolidated
(in millions)
Three months ended September 30, 2017
Revenues - external customers
Premiums:
Individual Medicare Advantage $ 8,077
$ —
$ —
$ —
$ —
$ —
$ 8,077
Group Medicare Advantage 1,272
—
—
—
—
—
1,272
Medicare stand-alone PDP 921
—
—
—
—
—
921
Total Medicare 10,270
—
—
—
—
—
10,270
Fully-insured 121
1,370
—
224
—
—
1,715
Specialty —
331
—
—
—
—
331
Medicaid and other 630
—
—
—
9
—
639
Total premiums 11,021
1,701
—
224
9
—
12,955
Services revenue:
Provider —
—
60
—
—
—
60
ASO and other 2
140
—
—
1
—
143
Pharmacy —
—
20
—
—
—
20
Total services revenue 2
140
80
—
1
—
223
Total revenues - external customers 11,023
1,841
80
224
10
—
13,178
Intersegment revenues
Services —
5
4,339
—
—
(4,344 ) —
Products —
—
1,572
—
—
(1,572 ) —
Total intersegment revenues —
5
5,911
—
—
(5,916 ) —
Investment income 23
7
9
1
22
42
104
Total revenues 11,046
1,853
6,000
225
32
(5,874 ) 13,282
Operating expenses:
Benefits 9,294
1,354
—
147
34
(187 ) 10,642
Operating costs 1,081
385
5,726
49
3
(5,556 ) 1,688
Depreciation and amortization 61
21
34
3
—
(25 ) 94
Total operating expenses 10,436
1,760
5,760
199
37
(5,768 ) 12,424
Income (loss) from operations 610
93
240
26
(5 ) (106 ) 858
Interest expense —
—
—
—
—
59
59
Income (loss) before income taxes $ 610
$ 93
$ 240
$ 26
$ (5 ) $ (165 ) $ 799

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)


	Insurance		CenterWell		Eliminations/ Corporate		Consolidated
Three months ended March 31, 2022	(in millions)
External Revenues
Premiums:
Individual Medicare Advantage	$	17,052	$	—	$	—	$	17,052
Group Medicare Advantage	1,875		—		—		1,875
Medicare stand-alone PDP	639		—		—		639
Total Medicare	19,566		—		—		19,566
Commercial fully-insured	1,140		—		—		1,140
Specialty benefits	261		—		—		261
Medicare Supplement	182		—		—		182
Medicaid and other	1,554		—		—		1,554
Total premiums	22,703		—		—		22,703
Services revenue:


Home solutions	—		726		—		726
Provider services	—		113		—		113
Commercial ASO	77		—		—		77
Military and other	127		—		—		127
Pharmacy solutions	—		221		—		221
Total services revenue	204		1,060		—		1,264
Total external revenues	22,907		1,060		—		23,967
Intersegment revenues
Services	14		857		(871)		—
Products	—		2,446		(2,446)		—
Total intersegment revenues	14		3,303		(3,317)		—
Investment income (loss)	46		2		(45)		3
Total revenues	22,967		4,365		(3,362)		23,970
Operating expenses:
Benefits	19,734		—		(109)		19,625
Operating costs	2,087		3,948		(3,149)		2,886

Depreciation and amortization	150		47		(27)		170
Total operating expenses	21,971		3,995		(3,285)		22,681
Income (loss) from operations	996		370		(77)		1,289

Interest expense	—		—		90		90
Other income, net	—		—		(21)		(21)
Income (loss) before income taxes and equity in net losses	996		370		(146)		1,220
Equity in net losses	—		(4)		—		(4)
Segment earnings (loss)	$	996	$	366	$	(146)	$	1,216
Net loss (income) attributable to noncontrolling interests	—		—		—		—
Segment earnings (loss) attributable to Humana	$	996	$	366	$	(146)	$	1,216

Retail Group and Specialty Healthcare
Services Individual Commercial Other
Businesses Eliminations/
Corporate Consolidated
(in millions)
Three months ended September 30, 2016
Revenues - external customers
Premiums:
Individual Medicare Advantage $ 7,977
$ —
$ —
$ —
$ —
$ —
$ 7,977
Group Medicare Advantage 1,067
—
—
—
—
—
1,067
Medicare stand-alone PDP 1,004
—
—
—
—
—
1,004
Total Medicare 10,048
—
—
—
—
—
10,048
Fully-insured 109
1,350
—
882
—
—
2,341
Specialty —
318
—
—
—
—
318
Medicaid and other 652
2
—
—
10
—
664
Total premiums 10,809
1,670
—
882
10
—
13,371
Services revenue:
Provider —
—
69
—
—
—
69
ASO and other 2
147
—
—
1
—
150
Pharmacy —
—
8
—
—
—
8
Total services revenue 2
147
77
—
1
—
227
Total revenues - external customers 10,811
1,817
77
882
11
—
13,598
Intersegment revenues
Services —
5
4,741
—
—
(4,746 ) —
Products —
—
1,580
—
—
(1,580 ) —
Total intersegment revenues —
5
6,321
—
—
(6,326 ) —
Investment income 22
7
8
—
17
42
96
Total revenues 10,833
1,829
6,406
882
28
(6,284 ) 13,694
Operating expenses:
Benefits 9,031
1,352
—
727
26
(236 ) 10,900
Operating costs 1,143
421
6,073
144
4
(6,046 ) 1,739
Merger termination fee and related costs, net —
—
—
—
—
20
20
Depreciation and amortization 51
19
36
9
—
(29 ) 86
Total operating expenses 10,225
1,792
6,109
880
30
(6,291 ) 12,745
Income (loss) from operations 608
37
297
2
(2 ) 7
949
Interest expense —
—
—
—
—
47
47
Income (loss) before income taxes $ 608
$ 37
$ 297
$ 2
$ (2 ) $ (40 ) $ 902

Table of Contents

Humana Inc.

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

Retail Group and Specialty Healthcare
Services Individual Commercial Other
Businesses Eliminations/
Corporate Consolidated
(in millions)
Nine months ended September 30, 2017
Revenues - external customers
Premiums:
Individual Medicare Advantage $ 24,735
$ —
$ —
$ —
$ —
$ —
$ 24,735
Group Medicare Advantage 3,867
—
—
—
—
—
3,867
Medicare stand-alone PDP 2,787
—
—
—
—
—
2,787
Total Medicare 31,389
—
—
—
—
—
31,389
Fully-insured 357
4,098
—
754
—
—
5,209
Specialty —
976
—
—
—
—
976
Medicaid and other 1,954
—
—
—
28
—
1,982
Total premiums 33,700
5,074
—
754
28
—
39,556
Services revenue:
Provider —
—
193
—
—
—
193
ASO and other 6
444
—
—
5
—
455
Pharmacy —
—
58
—
—
—
58
Total services revenue 6
444
251
—
5
—
706
Total revenues - external customers 33,706
5,518
251
754
33
—
40,262
Intersegment revenues
Services —
15
12,958
—
—
(12,973 ) —
Products —
—
4,706
—
—
(4,706 ) —
Total intersegment revenues —
15
17,664
—
—
(17,679 ) —
Investment income 72
25
25
3
64
127
316
Total revenues 33,778
5,558
17,940
757
97
(17,552 ) 40,578
Operating expenses:
Benefits 29,017
3,952
—
389
95
(596 ) 32,857
Operating costs 2,998
1,178
17,083
151
9
(16,725 ) 4,694
Merger termination fee and related costs, net —
—
—
—
—
(947 ) (947 )
Depreciation and amortization 176
63
103
10
—
(74 ) 278
Total operating expenses 32,191
5,193
17,186
550
104
(18,342 ) 36,882
Income (loss) from operations 1,587
365
754
207
(7 ) 790
3,696
Interest expense —
—
—
—
—
166
166
Income (loss) before income taxes $ 1,587
$ 365
$ 754
$ 207
$ (7 ) $ 624
$ 3,530

~~Humana Inc.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~(Unaudited)~~

Retail Group and Specialty Healthcare
Services Individual Commercial Other
Businesses Eliminations/
Corporate Consolidated
(in millions)
Nine months ended September 30, 2016
Revenues - external customers
Premiums:
Individual Medicare Advantage $ 24,054
$ —
$ —
$ —
$ —
$ —
$ 24,054
Group Medicare Advantage 3,229
—
—
—
—
—
3,229
Medicare stand-alone PDP 3,058
—
—
—
—
—
3,058
Total Medicare 30,341
—
—
—
—
—
30,341
Fully-insured 319
4,044
—
2,799
—
—
7,162
Specialty —
957
—
—
—
—
957
Medicaid and other 1,960
12
—
—
29
—
2,001
Total premiums 32,620
5,013
—
2,799
29
—
40,461
Services revenue:
Provider —
—
214
—
—
—
214
ASO and other 5
500
1
—
7
—
513
Pharmacy —
—
22
—
—
—
22
Total services revenue 5
500
237
—
7
—
749
Total revenues - external customers 32,625
5,513
237
2,799
36
—
41,210
Intersegment revenues
Services —
17
14,292
—
—
(14,309 ) —
Products —
—
4,373
—
—
(4,373 ) —
Total intersegment revenues —
17
18,665
—
—
(18,682 ) —
Investment income 68
19
22
3
48
131
291
Total revenues 32,693
5,549
18,924
2,802
84
(18,551 ) 41,501
Operating expenses:
Benefits 27,991
3,876
—
2,545
82
(688 ) 33,806
Operating costs 3,294
1,278
17,989
465
12
(17,866 ) 5,172
Merger termination fee and related costs, net —
—
—
—
—
81
81
Depreciation and amortization 145
62
107
27
—
(78 ) 263
Total operating expenses 31,430
5,216
18,096
3,037
94
(18,551 ) 39,322
Income (loss) from operations 1,263
333
828
(235 ) (10 ) —
2,179
Interest expense —
—
—
—
—
141
141
Income (loss) before income taxes $ 1,263
$ 333
$ 828
$ (235 ) $ (10 ) $ (141 ) $ 2,038

~~Humana Inc.~~

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward–looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our ~~2016~~2022 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February ~~17, 2017,~~16, 2023, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward–looking statements.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and ~~well-being~~well being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, - such as ~~in-home~~in home care, behavioral health, pharmacy services, data analytics and wellness solutions, - combine to produce a simplified experience that makes health care easier to navigate and more effective.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking

total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding ~~Merger termination fee and related costs, net, and~~ depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the next 18 to 24 months.

Sale of ~~Closed Block~~Hospice and Personal Care Divisions

On August 11, 2022, we completed the sale of ~~Commercial Long-Term Care Insurance Business~~a 60% interest in Gentiva, formerly Kindred, Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $237 million.

~~On November 6, 2017, we entered into a definitive agreement to sell the stock~~

Table of our wholly-owned subsidiary, KMG America Corporation, or KMG, to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG’s subsidiary, Kanawha Insurance Company, or KIC, includes our closed block of non-strategic commercial long-term care insurance policies that serves approximately 30,100 policyholders. Based on the termsContents

COVID-19

The emergence and spread of the ~~definitive agreement~~novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. During periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we ~~expect to record a net loss~~experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the ~~sale~~Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of ~~KMG of approximately $400 million, or $2.75 per diluted common share. The estimated loss includes~~our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a pretax loss of approximately $900 million, offset by the expected tax benefit of approximately $500 million. We will fund the transaction with approximately $203 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $150 million of statutory capital with the sale, which together should be more than offset by the estimated $500 million cash savings associated with the expected tax treatmentresult of the ~~sale.~~ COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

The ~~KMG transaction~~COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency is ~~anticipated~~set to ~~close by the third quarter~~expire on May 11, 2023.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of ~~2018 subject to customary closing conditions, including South Carolina Department of Insurance approval. There can be no assurance~~our healthcare services capabilities in 2023, we ~~will obtain regulatory approvals needed to sell the business or do so under terms acceptable to us.~~

~~Workforce Optimization~~

~~We have been~~ committed to drive additional value for the enterprise through cost saving, productivity initiatives, ~~designed to promote operational excellence, accelerate our strategy, fund critical initiatives~~ and advance our growth objectives. During the third quarter of 2017, we initiated a voluntary early retirement program and an involuntary workforce reduction program that will allow us to achieve these objectives and position us for the future. These programs are expected to impact approximately 2,700 associates, or 5.7%, of our workforce.value acceleration from previous investments. As a result of these initiatives, we recorded ~~estimated~~ charges of ~~$124~~$473 million ~~or $0.54 per diluted common share. At October~~for the year-ended December 31, ~~2017, we had approximately 47,200 employees.~~2022. These charges primarily relate to $248 million in asset impairments, including software and abandonment, and $116 million of severance charges in connection with workforce optimization. The ~~estimated~~remainder of the charges primarily relate to external consulting fees. These charges were recorded at the corporate level and not allocated to the segments. ~~This charge is included with operating costs~~We did not record any charges in the condensed consolidated statements of income for the three and nine month periods ended September 30, 2017. Payments under these programs are made upon termination during the early retirement or severance pay period, primarily starting as of the beginning of the first quarter of ~~2018. We expect this liability to be primarily paid within the next 12 months and classified it as a current liability, included~~2022, with no recurring charges in ~~trade accounts payable and accrued expenses.~~

~~Aetna Merger~~

On July 2, 2015, we entered into an Agreement and Plan of Merger, which we refer to in this report as the Merger Agreement, with Aetna Inc. and certain wholly owned subsidiaries of Aetna Inc., which we refer to collectively as Aetna, which set forth the terms and conditions under which we agreed to merge with, and become a wholly owned subsidiary of Aetna, a transaction we refer to in this report as the Merger.

On July 21, 2016, the U.S. Department of Justice and the attorneys general of certain U.S. jurisdictions filed a civil antitrust complaint in the U.S. District Court for the District of Columbia against us and Aetna, alleging that the Merger would violate Section 7 of the Clayton Antitrust Act and seeking a permanent injunction to prevent the Merger from being completed. On January 23, 2017, the Court ruled in favor of the DOJ and granted a permanent injunction of the proposed transaction. On February 14, 2017, we and Aetna agreed to mutually terminate the Merger Agreement, as our Board determined that an appeal of the Court's ruling would not be in the best interest of our stockholders. On February 16, 2017, under the terms of the Merger Agreement, we received a breakup fee of $1 billion from Aetna, which is included in our condensed consolidated statement of income in the line captioned Merger termination fee and related costs, net.2023.

Business Segments

During ~~the three months ended March 31, 2017,~~December 2022, we realigned ~~certain of~~ our businesses ~~among our reportable segments to correspond with internal management reporting changes~~into two distinct segments: Insurance and ~~our~~CenterWell. The Insurance segment includes the businesses that were previously ~~announced planned exit from~~included in the ~~Individual Commercial medical business on January 1, 2018. Additionally, we renamed our Group segment to the~~Retail and Group and Specialty ~~segment, and began presenting~~segments, as well as the ~~Individual Commercial~~Pharmacy Benefit Manager, or PBM, business results as a separate segment rather than as part of the Retail segment. Specialty health insurance benefits, including dental, vision, other supplement health, and financial protection products, marketed to individuals are nowwhich was previously included in the Group and Specialty segment. Specialty health insurance benefits marketed to employer groups continue to be included in the Group and Specialty segment. As a result of this realignment, our reportable segments now include Retail, Group and Specialty, Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and ~~Individual Commercial.~~ home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization.Prior period segment financial information has been recast to conform to the ~~2017~~2023 presentation. ~~See~~For a recast of prior period segment financial information, refer to Note 1514 to the ~~condensed consolidated financial statements~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this ~~report for segment financial information.~~Form 10-Q.

~~These segments~~CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

Table of Contents

health ~~and voluntary insurance~~ benefits, ~~and financial protection products,~~ as well as administrative services only, or ~~ASO products.~~ASO. In addition, our ~~Group and Specialty~~Insurance segment includes ~~military services~~our Military business, primarily our ~~TRICARE South~~T-2017 East Region ~~contract. The Healthcare Services segment includes services offered to our health plan members~~contract, as well as ~~to third parties, including~~the operations of our PBM business.

The results of each segment are measured by income ~~before income taxes.~~(loss) from operations. Transactions between reportable segments primarily consist of sales of services rendered by our ~~Healthcare Services~~CenterWell segment, primarily pharmacy, provider, and ~~clinical care~~home services, to our ~~Retail, Group and Specialty, and Individual Commercial~~Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

COVID-19 disrupted the pattern of our quarterly earnings and operating cash flows largely due to the temporary deferral of non-essential care which resulted in reductions in non-COVID-19 hospital admissions and lower overall healthcare system utilization during higher levels of COVID-19 hospital admissions. At the same time, during periods of increased incidences of COVID-19, COVID-19 treatment and testing costs increase. Similar impacts and seasonal disruptions from either higher or lower utilization are expected to persist as we respond to and recover from the COVID-19 global health crisis.

One of the product offerings of our ~~Retail~~Insurance segment is Medicare stand-alone prescription drug plans, or ~~PDPs,~~PDP, under the Medicare Part D program. Our quarterly ~~Retail~~Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of ~~low-income~~low income senior members as well as year-over-year changes in the mix of membership in our ~~stand-alone~~standalone PDP products affects the quarterly benefit ratio pattern.

The Insurance segment also experiences seasonality in the commercial fully-insured product offering. The effect on the Insurance segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. The Employer Group Commercial Fully-Insured business decreased our Insurance segment benefit ratio by 30 basis points and 20 basis points for the three months ended March 31, 2023 and 2022, respectively. The Employer Group Commercial Fully-Insured business increased our Insurance segment operating cost ratio by 40 basis points and 50 basis points for the three months ended March 31, 2023 and 2022, respectively.

In addition, the ~~Retail~~Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season.

~~Our Group and Specialty segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite~~

Table of Medicare stand-alone PDP in the Retail segment, with the Group and Specialty segment’s benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses.Contents

Certain of our fully-insured individual commercial medical products in our Individual Commercial segment experience seasonality in the benefit ratio akin to the Group and Specialty segment, including the effect of existing previously underwritten members transitioning to policies compliant with the Health Care Reform Law with us and other carriers. As previously underwritten members transition, it results in policy lapses and the release of reserves for future policy benefits partially offset by the recognition of previously deferred acquisition costs. The recognition of a

premium deficiency reserve for our Individual Commercial medical business compliant with the Health Care Reform Law in the fourth quarter of 2015, and subsequent changes in estimate, also impacted the quarterly benefit ratio pattern for this business in 2016.

~~2017~~2023 Highlights

~~Consolidated~~

•Our consolidated pretax results for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016, were primarily impacted by the estimated charges associated with voluntary and involuntary workforce reduction programs and lower pretax earnings in the Healthcare Services segment, partially offset by year-over-year improvement in earnings for our Group and Specialty segment as well as Medicare Advantage and Individual Commercial businesses. Our consolidated pretax results for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016, primarily reflects the net gain associated with the terminated Merger Agreement, mainly the break-up fee, along with the year-over year improvement in earnings for our Group and Specialty segment as well as Medicare Advantage and Individual Commercial businesses. These were partially offset by lower pretax earnings in the Healthcare Services segment and the recording of estimated charges associated with voluntary and involuntary workforce reduction programs during the three months ended September 30, 2017.

Year-over-year comparisons of diluted earnings per common share reflect the same factors impacting our consolidated pretax income comparisons year-over-year as well as the beneficial effect of the lower effective tax rate in light of pricing and benefit design assumptions associated with the 2017 temporary suspension of the health insurance industry fee. In addition the year-over-year comparisons were favorably impacted by lower number of shares, primarily reflecting share repurchases.

~~Our 2017 results through September 30, 2017 reflect the continued implementation of our~~ strategy ~~to offer~~offers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At ~~September 30, 2017,~~March 31, 2023, approximately ~~1,877,800~~3,505,100 members, or ~~65.9%~~68%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to ~~1,816,300~~3,053,600 members, or ~~64.0%~~67%, at ~~December~~March 31, ~~2016 and 1,786,100 members,~~2022.

•Net income was $1.2 billion, or ~~63.1%, at September 30, 2016.~~

We recorded a net gain associated with the terminated Merger Agreement, consisting primarily of the break-up fee, of approximately $947 million, or $4.33 per diluted common share during the nine months ended September 30, 2017. We recorded transaction costs in connection with the Merger of approximately $20 million, or $0.12$9.87 per diluted common share, and ~~$81~~$930 million, or ~~$0.49~~$7.29 per diluted common share, ~~during the three and nine months ended September 30, 2016, respectively. Certain costs associated with the Merger were previously not deductible~~ for ~~tax purposes, but became deductible, and were recorded as such in~~ the three months ended March 31, ~~2017 as a result of the termination of the Merger Agreement.~~

~~Year-over-year~~2023, and 2022, respectively. These comparisons of results are also impacted by the recognition of a premium deficiency reserve for our Individual Commercial segment related to certain of our 2016 policies as discussed in the Individual Commercial segment highlights that follow. During the nine months ended September 30, 2016, we increased the premium deficiency reserve by $208 million, or $0.86 per diluted common share.

The annual health insurance industry fee has been suspended for calendar year 2017 but is scheduled to resume in calendar year 2018. Operating cost associated with the health insurer fee attributable to the three and nine months ended September 30, 2016 was $231 million and $687 million, respectively. This fee is not deductible for tax purposes, which significantly increased our effective income tax rate. The one-year suspension in 2017 of the health insurer fee has significantly reduced our operating costs and effective tax rate during the three and nine months ended September 30, 2017.

On March 1, 2017, a court ordered the liquidation of Penn Treaty (an unaffiliated long-term care insurance company), which triggered assessments from state guaranty associations that resulted in our recording a $54 million, or $0.23 per diluted common share, estimate in operating costs in the three months ended March 31, 2017.

During the third quarter of 2017 we recorded estimated charges of $124 million, or $0.54 per diluted common share associated with both voluntary and involuntary workforce reduction programs that are expected to impact approximately 2,700 associates, or 5.7%, of our workforce. This charge is included with operating costs in the condensed consolidated statement of income for the three and nine month periods ended September 30, 2017.

During the nine months ended September 30, 2017, cash flow provided by operations was $7.0 billion as compared to $4.7 billion for the nine months ended September 30, 2016. Our operating cash flows for the nine months ended September 30, 2017 were significantly impacted by ~~the receipt of the $1 billion Merger termination fee, net of related expenses~~put/call valuation adjustments associated with non-consolidating minority interest investments, transaction and integration costs, and the ~~portion~~change in the fair value of publicly-traded equity securities. The impact of these adjustments to our consolidated income before income taxes ~~paid to date. Our operating cash flows were also significantly impacted~~and equity in both periods by the early receipt of the Medicare premium remittance for October 2017 of $3.1 billion in September 2017 and the receipt of the Medicare premium remittance for October 2016 of $3.0 billion in September 2016 because the payment dates of October 2017 and October 2016 fell on a weekend. Excluding the Merger termination fee and the timing of the Medicare premium remittances, our operating cash flows were positively impacted by highernet earnings and ~~the timing of working capital items. See further discussion under the section titled "Liquidity" in this report.~~

~~Retail~~

~~On April 3, 2017, CMS issued its announcement of 2018 Medicare Advantage Capitation Rates and Medicare Advantage and Part D payment policies and Final Call Letter, which we refer to collectively~~diluted earnings per common share was as ~~the Final Rate Notice. We expect the Final Rate Notice to result in a 0.45% rate increase for Humana versus CMS’ estimate~~follows for the ~~sector~~2023and 2022 quarter:


	For the three months ended March 31,
	2023		2022
Consolidated income before income taxes and equity in net earnings:

Put/call valuation adjustments associated with our non consolidating minority interest investments	$	53	$	(21)
Transaction and integration costs	(51)		17
Change in the fair value of publicly-traded equity securities	1		109


Total	$	3	$	105

	For the three months ended March 31,
	2023		2022
Diluted earnings per common share:

Put/call valuation adjustments associated with our non consolidating minority interest investments	$	0.42	$	(0.16)
Transaction and integration costs	(0.41)		0.13
Change in the fair value of publicly-traded equity securities	(0.01)		0.85


Tax impact of all transactions	(0.11)		(0.18)
Total	$	(0.11)	$	0.64

Table of 0.85% increase on a comparable basis. The rate increase excludes the impact of Star quality bonus ratings, the impact of encounter data weighting in risk score calculations and estimates of changes in revenue associated with increased accuracy of risk coding. The primary difference between the estimates is the impact of fee-for-service county rebasing/re-pricing by CMS.Contents

~~Group and Specialty Segment~~

On March 2, 2017, we received notice that the Defense Health Agency, or DHA, had exercised its option to extend the TRICARE South Region contract through March 31, 2018. On July 21, 2016, we were notified by the DHA that we were awarded the contract for the new TRICARE East Region, which is a consolidation of the former North and South Regions, with delivery of health care services expected to commence on October 1, 2017. On March 30, 2017, we received notice that the DHA is moving the date upon which delivery of health care services is expected to commence under the new TRICARE East Region contract from October 1, 2017 to January 1, 2018.

~~Healthcare Services Segment~~

At September 30, 2017, approximately 51,500 primary care providers were in value-based relationships, an increase of 3.8% from 49,600 at September 30, 2016 and an increase of 2.2% from 50,400 at December 31, 2016. At September 30, 2017, 65.9% of our individual Medicare Advantage members were in value-based relationships compared to 63.1% at September 30, 2016 and 64.0% at December 31, 2016.

Medicare Advantage and dual demonstration program membership enrolled in a Humana chronic care management program was 825,200 at September 30, 2017, a decrease of 21.0% from 1,044,700 at September 30, 2016, and 24.9% from 1,099,200 at December 31, 2016. We have undergone an optimization process that ensures the appropriate level of member interaction with clinicians to drive quality outcomes, which has resulted in reduced segment earnings but higher returns on investment.

Health Care Reform

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance ~~industry. Certain significant provisions of the Health Care Reform Law include,~~industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of ~~federally-facilitated~~federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial ~~values. In addition,~~values, and changes to the ~~Health Care Reform Law established insurance industry assessments, including an annual health insurance industry fee~~Part D prescription drug benefit design.

It is reasonably possible that these laws and a three-year $25 billion industry wide commercial reinsurance fee, which ends in 2017. The annual health insurance industry fee, which is not deductible for income tax purposes, has been suspended for calendar year 2017, but is scheduled to resume in calendar year 2018.

In addition, the Health Care Reform Law expands federal oversight of health plan premium rates. Financing for these reforms comes, in part, from material additional fees and taxes on us (as discussed above) and other health plans and individuals which began in 2014,regulations, as well as ~~reductions in certain levels of payments to us and~~ other ~~health plans under Medicare as described in our 2016 Form 10-K.~~

As noted above, the Health Care Reform Law required the establishment of health insurance exchanges for individuals and small employers to purchase health insurance that became effective January 1, 2014, with an annual open enrollment period. Insurers participating on the health insurance exchanges must offer a minimum level of benefits and are subject to guidelines on setting premium rates and coverage limitations. We may be adversely selected by individuals who have a higher acuity level than the anticipated pool of participants in this market. In addition, the risk corridor, reinsurance, and risk adjustment provisions of the Health Care Reform Law, established to apportion risk for insurers, may not be effective in appropriately mitigating the financial risks related to our products. In addition,current or future legislative, judicial or regulatory changes (including further legislative or regulatory action taken in response to the implementation of the Health Care Reform Law that allowed individuals to remain in plans that are not compliant with the Health Care Reform Law or to enroll outside of the annual enrollment period may have an adverse effect on our pool of participants in the health insurance exchange. In addition, states may imposeCOVID-19) including restrictions on our ability to ~~increase rates. All~~manage our provider network or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of ~~these factors~~various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, or increases in regulation of our prescription drug benefit businesses, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position ~~or cash flows if~~(including our ~~premiums are not adequate or do not appropriately reflect~~ability to maintain the acuity of these individuals. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions used in setting premium rates could have a material adverse effect on our results of operations, financial position, and cash flows and could impact our decision to participate or continue in the program in certain states. For 2017, we are offering

on-exchange individual commercial medical plans in 11 states, a reduction from the 15 states in which we offered on-exchange coverage in 2016. In addition, we discontinued substantially all Health Care Reform Law compliant off-exchange individual commercial medical plans effective January 1, 2017. As previously discussed, on February 14, 2017, we announced we are exiting our Individual Commercial medical business January 1, 2018.

If we fail to effectively implement our operational and strategic initiatives with respect to the implementation of the Health Care Reform Law, our business may be materially adversely affected. Additionally, potential legislative changes, including the Trump Administration's October 12, 2017 announcement to end cost-sharing reduction benefits effective for October 2017 and beyond in all states as well as activities to repeal or replace the Health Care Reform Law, creates uncertainty for our business, and we cannot predict when, or in what form, such legislative changes may occur. We may be unable to adjust our product offerings, geographic footprint, or pricing during any given year such legislative changes occur in sufficient time to mitigate any adverse effects.

On November 10, 2016, the U.S. Court of Federal Claims ruled in favor of the government in one of a series of cases filed by insurers, unrelated to us, against HHS to collect risk corridor payments, rejecting all of the insurers statutory, contract and Constitutional claims for payment. On November 18, 2016, HHS issued a memorandum indicating a significant funding shortfall for the 2015 coverage year, the second consecutive year of significant shortfalls. Given the successful challenge of the risk corridor provisions in court, Congressional inquiries into the funding of the risk corridor program, and significant funding shortfalls under the first two years of the program, during the fourth quarter of 2016 we wrote-off $583 million in risk corridor receivables outstanding as of September 30, 2016, including $415 million associated with the 2014 and 2015 coverage years. From inception of the risk corridor program through September 30, 2017, we collected approximately $39 million from CMS for risk corridor receivables associated with the 2014 coverage year funded by HHS in accordance with previous guidance, utilizing funds HHS collected from us and other carriers under the risk corridor program. At September 30, 2017, we estimate that we are entitled to collect a total of $611 million from HHS under the commercial risk corridor program for the 2014 through 2016 program years. On November 2, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, on behalfvalue of our health plans seeking recovery from the federal government of approximately $611 million in payments under the risk corridor premium stabilization program established under Health Care Reform, for years 2014, 2015goodwill); and ~~2016.~~our cash flows.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our ~~Healthcare Services~~CenterWell segment, primarily pharmacy, provider, and ~~clinical care~~home services, to our ~~Retail, Group and Specialty, and Individual Commercial~~Insurance segment customers and are described in Note 1514 to the condensed consolidated financial statements included in this report.

Table of Contents

Comparison of Results of Operations for ~~2017~~2023 and ~~2016~~2022

The following discussion primarily deals with our results of operations for the three months ended ~~September 30, 2017,~~March 31, 2023, or the ~~2017~~2023 quarter and the three months ended ~~September 30, 2016,~~March 31, 2022, or the ~~2016 quarter, the nine months ended September 30, 2017, or the 2017 period, and the nine months ended September 30, 2016, or the 2016 period.~~2022 quarter.

Consolidated



								Change
	Three months ended March 31,						Three months ended March 31, 2023 vs 2022
	2023			2022				$		%
	($ in millions, except per common share results)
Revenues:
Premiums:
Insurance	$	25,550		$	22,703			$	2,847	12.5	%

Total premiums revenue	25,550			22,703				2,847		12.5	%
Services:
Insurance	242			204				38		18.6	%
CenterWell	757			1,060				(303)		(28.6)	%
Total services revenue	999			1,264				(265)		(21.0)	%
Investment income	193			3				190		6,333.3	%
Total revenues	26,742			23,970				2,772		11.6	%
Operating expenses:
Benefits	21,858			19,625				2,233		11.4	%
Operating costs	2,979			2,886				93		3.2	%
Depreciation and amortization	186			170				16		9.4	%
Total operating expenses	25,023			22,681				2,342		10.3	%
Income from operations	1,719			1,289				430		33.4	%

Interest expense	113			90				23		25.6	%
Other income, net	(8)			(21)				(13)		(61.9)	%
Income before income taxes and equity in net earnings	1,614			1,220				394		32.3	%
Provision for income taxes	359			286				73		25.5	%
Equity in net losses	(17)			(4)				(13)		325.0	%
Net income	$	1,238		$	930			$	308	33.1	%
Diluted earnings per common share	$	9.87		$	7.29			$	2.58	35.4	%
Benefit ratio (a)	85.5		%	86.4		%				(0.9)	%
Operating cost ratio (b)	11.2		%	12.0		%				(0.8)	%
Effective tax rate	22.5		%	23.5		%				(1.0)	%

For the three months ended September 30, Change
2017 2016 Dollars Percentage
(dollars in millions, except per common share results)
Revenues:
Premiums:
Retail $ 11,021
$ 10,809
$ 212
2.0 %
Group and Specialty 1,701
1,670
31
1.9 %
Individual Commercial 224
882
(658 ) (74.6 )%
Other Businesses 9
10
(1 ) (10.0 )%
Total premiums 12,955
13,371
(416 ) (3.1 )%
Services:
Retail 2
2
—
— %
Group and Specialty 140
147
(7 ) (4.8 )%
Healthcare Services 80
77
3
3.9 %
Other Businesses 1
1
—
— %
Total services 223
227
(4 ) (1.8 )%
Investment income 104
96
8
8.3 %
Total revenues 13,282
13,694
(412 ) (3.0 )%
Operating expenses:
Benefits 10,642
10,900
(258 ) (2.4 )%
Operating costs 1,688
1,739
(51 ) (2.9 )%
Merger termination fee and related costs, net —
20
(20 ) (100.0 )%
Depreciation and amortization 94
86
8
9.3 %
Total operating expenses 12,424
12,745
(321 ) (2.5 )%
Income from operations 858
949
(91 ) (9.6 )%
Interest expense 59
47
12
25.5 %
Income before income taxes 799
902
(103 ) (11.4 )%
Provision for income taxes 300
452
(152 ) (33.6 )%
Net income $ 499
$ 450
$ 49
10.9 %
Diluted earnings per common share $ 3.44
$ 2.98
$ 0.46
15.4 %
Benefit ratio(a)
82.1 % 81.5 % 0.6 %
Operating cost ratio(b)
12.8 % 12.8 % — %
Effective tax rate 37.5 % 50.1 % (12.6 )%

(a)Represents ~~total~~ benefits expense as a percentage of premiums revenue.

(b)Represents ~~total~~ operating costs ~~excluding Merger termination fee and related costs, net, and depreciation and amortization,~~ as a percentage of total revenues less investment income.

Table of Contents

For the nine months ended
September 30, Change
2017 2016 Dollars Percentage
(dollars in millions, except per common share results)
Revenues:
Premiums:
Retail $ 33,700
$ 32,620
$ 1,080
3.3 %
Group and Specialty 5,074
5,013
61
1.2 %
Individual Commercial 754
2,799
(2,045 ) (73.1 )%
Other Businesses 28
29
(1 ) (3.4 )%
Total premiums 39,556
40,461
(905 ) (2.2 )%
Services:
Retail 6
5
1
20.0 %
Group and Specialty 444
500
(56 ) (11.2 )%
Healthcare Services 251
237
14
5.9 %
Other Businesses 5
7
(2 ) (28.6 )%
Total services 706
749
(43 ) (5.7 )%
Investment income 316
291
25
8.6 %
Total revenues 40,578
41,501
(923 ) (2.2 )%
Operating expenses:
Benefits 32,857
33,806
(949 ) (2.8 )%
Operating costs 4,694
5,172
(478 ) (9.2 )%
Merger termination fee and related costs, net (947 ) 81
(1,028 ) (1,269.1 )%
Depreciation and amortization 278
263
15
5.7 %
Total operating expenses 36,882
39,322
(2,440 ) (6.2 )%
Income from operations 3,696
2,179
1,517
69.6 %
Interest expense 166
141
25
17.7 %
Income before income taxes 3,530
2,038
1,492
73.2 %
Provision for income taxes 1,266
1,023
243
23.8 %
Net income $ 2,264
$ 1,015
$ 1,249
123.1 %
Diluted earnings per common share $ 15.44
$ 6.73
$ 8.71
129.4 %
Benefit ratio (a)
83.1 % 83.6 % (0.5 )%
Operating cost ratio (b)
11.7 % 12.6 % (0.9 )%
Effective tax rate 35.9 % 50.2 % (14.3 )%


~~(a)~~	~~Represents total benefits expense as a percentage of premiums revenue.~~


~~(b)~~	~~Represents total operating costs, excluding Merger termination fee and related costs, net, and depreciation and amortization, as a percentage of total revenues less investment income.~~

Premiums Revenue

~~Summary~~

~~Net income was $499 million,~~Consolidated premiums revenue increased $2.8 billion, or ~~$3.44 per diluted common share,~~12.5%, from $22.7 billion in the ~~2017~~2022 quarter ~~compared~~ to ~~$450 million, or $2.98 per diluted common share,~~$25.6 billion in the ~~2016 quarter. The 2017~~2023 quarter ~~includes net income from our Individual Commercial segment of $0.11~~primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per diluted common share, as well as $0.55 per diluted common share beneficial effect of the lower tax rate in light of pricing and benefit design assumptions associated with the 2017 temporary suspension of the health insurance industry fee, excluding the Individual Commercial business impact.member individual Medicare Advantage premiums. These factors were partially offset by ~~$0.54 per diluted common share~~the phase-out of COVID-19 sequestration relief in estimated charges associated with both voluntary and involuntary workforce reduction programs. Net income was $2.3 billion, or $15.44 per diluted common share, in the 2017 period compared to $1.0 billion, or $6.73 per diluted common share, in the 2016 period. The 2017 period includes a net gain associated with the terminated Merger Agreement consisting primarily of the break-up fee representing $4.33 per diluted common share. In addition, the 2017 period includes net income from our Individual Commercial segment of $0.89 per diluted common share, as well as $1.60 per diluted common share beneficial effect of the lower tax rate in light of pricing and benefit design assumptions associated with the 2017 temporary suspension of the health insurance industry fee, excluding the Individual Commercial business impact. These were offset by $0.54 per diluted common share in estimated charges associated with both voluntary and involuntary workforce reduction programs,2022, as well as the estimated guaranty fund assessment expense to support the policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company) of $0.23 per diluted common share. Excluding the impact of the items above, the increaseyear-over-year decline in ~~the 2017 quarter and the 2017 period primarily was due to year-over-year improvement in our Retail segment pretax results as discussed in the detailed segment results discussion that follows.~~

~~Premiums Revenue~~

Consolidated premiums decreased $416 million, or 3.1%, from the 2016 quarter to $13.0 billion for the 2017 quarter and decreased $905 million, or 2.2%, from the 2016 period to $39.6 billion for the 2017 period. These decreases are primarily due to lower premiums in the Individual Commercial segment, partially offset by higher premiums in the Retail segment resulting from ourmembership associated with group commercial medical, group Medicare Advantage ~~business, as discussed in the detailed segment results discussion that follows.~~and stand-alone PDP products.

Services Revenue

Consolidated services revenue decreased ~~$4 million,~~$0.3 billion, or ~~1.8%~~21.0%, from $1.3 billion in the ~~2016~~2022 quarter to ~~$223 million for~~$1.0 billion in the ~~2017~~2023 quarter ~~and decreased $43 million, or 5.7%, from the 2016 period to $706 million for the 2017 period. These decreases are~~ primarily due to ~~a decrease~~the divestiture of the 60% ownership of Gentiva Hospice in ~~services revenue in the Group and Specialty segment as discussed in the detailed segment results discussion that follows.~~August 2022.

Investment Income

Investment income ~~totaled $104 million for the 2017 quarter, increasing $8~~increased $190 million, or ~~8.3%~~6333.3%, from ~~$96 million for the 2016 quarter. For the 2017 period, investment income totaled $316 million, increasing $25 million, or 8.6% , from $291~~$3 million in the ~~2016 period. These increases~~2022 quarter to $193 million in the 2023 quarter primarily ~~reflect higher average invested balances and~~due to an increase in interest ~~rates, partially offset by lower realized capital gains.~~income on our debt securities combined with the 2022 quarter decrease in the fair value of our publicly traded equity securities investments.

~~Benefits~~Benefit Expense

Consolidated benefits expense ~~was $10.6~~increased $2.2 billion, or 11.4%, from $19.6 billion in the 2022 quarter to $21.9 billion in the 2023 quarter. The consolidated benefit ratio decreased 90 basis points from 86.4% for the ~~2017~~2022 quarter ~~a decrease of $258 million from~~to 85.5% for the ~~2016 quarter. For the 2017 period, benefits expense was $32.9 billion, a decrease of $949 million from the 2016 period. These decreases are~~2023 quarter primarily due to aincreased individual Medicare Advantage premium yield, lower COVID-19 inpatient utilization in the 2023 quarter, and the corresponding decrease in average unit cost given the ~~Individual Commercial segment benefits expense, partially offset by an increase in~~additional 20% payment on these admissions during the ~~Retail and Group and Specialty segments benefits expense. We experienced~~Public Health Emergency, as well as higher favorable prior-period medical claims reserve development ~~related to prior fiscal years of $85 million~~ in the ~~2017 quarter as compared to $90 million~~2023 quarter. These factors were partially offset by investments in the ~~2016 quarter. In~~benefit design of our products for 2023. Further, the ~~2017 period, we experienced~~2023 quarter ratio continues to reflect a shift in line of business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio.

Consolidated benefits expense included $522 million of favorable prior-period medical claims reserve development ~~related to prior fiscal years of $430 million as compared to $525 million~~ in the ~~2016 period as discussed~~2023 quarter and $360 million of favorable prior-period medical claims development in the ~~detailed segment results discussion that follows.~~

The consolidated benefit ratio increased 60 basis points to 82.1% for the 2017 quarter compared to 81.5% for the 2016 quarter primarily due to the increase in the Retail segment benefit ratio, partially offset by decreases in the Group

and Specialty and Individual Commercial segment benefit ratios as discussed in the segment results of operation discussion that follows. The consolidated benefit ratio for the 2017 period was 83.1%, a 50 basis point decrease from 83.6% for the 2016 period, primarily due to the decrease in the Individual Commercial segment benefit ratio, partially offset by the increase in the Retail and Group and Specialty segment benefit ratio as discussed in the segment results of operation discussion that follows. Favorable prior-period2022 quarter. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 70200 basis points in ~~each of~~ the ~~2017~~2023 quarter and ~~the 2016 quarter. Favorable prior-period medical claims reserve development~~ decreased the consolidated benefit ratio by approximately ~~110~~160 basis points in the ~~2017 period versus approximately 130 basis points in the 2016 period.~~2022 quarter.

Operating Costs

Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.

Consolidated operating costs ~~decreased $51 million,~~increased $0.1 billion, or ~~2.9%~~3.2%, ~~during~~from $2.9 billion in the ~~2017~~2022 quarter ~~compared~~ to $3.0 billion in the 2016 quarter primarily due to the temporary suspension of the health insurance industry fee for the calendar year 2017, and lower Individual Commercial membership, partially offset by the estimated charges associated with both voluntary and involuntary workforce reduction programs recorded during the 20172023 quarter. Consolidated operating costs decreased $478 million, or 9.2%, during the 2017 period compared to the 2016 period primarily due to the temporary suspension of the health insurance industry fee for the calendar year 2017, and lower Individual Commercial membership, partially offset by the estimated charges associated with both voluntary and involuntary workforce reduction programs as well as the estimated guaranty fund assessment expense recorded to support the policyholder obligations of Penn Treaty (an unaffiliated long-term care insurance company).

The consolidated operating cost ratio decreased 80 basis points from 12.0% for the ~~2017~~2022 quarter ~~of 12.8% was unchanged from~~to 11.2% for the ~~2016 quarter. The year-over-year comparison was favorably impacted by~~2023 quarterprimarily due to the ~~temporary suspension~~divestiture of the ~~health insurance industry fee for~~60% ownership of Gentiva Hospice in August 2022, which carried a significantly higher operating cost ratio compared to the calendar year 2017, offset by the loss of scale efficiency from market exits in the 2017 period associated with the Individual Commercial product, the estimated charges associated with both voluntary and involuntary workforce reduction programs recorded in the 2017 quarter, and the increase in employee compensation costs resulting from the continued strong performance. Thehistorical consolidated operating cost ratio, for the 2017 period decreased 90 basis points to 11.7% from 12.6% in the 2016 period primarily due to the temporary suspension of the health insurance industry fee for the calendar year 2017 as well as operating costscale efficiencies ~~partially offset by the loss of scale efficiency from market exits in the 2017 period~~ associated with ~~the Individual Commercial product, the estimated charges associated with both voluntary and involuntary workforce reduction programs recorded~~growth in ~~the 2017 quarter,~~individual Medicare Advantage membership, as well as the impact of initiatives related to the ~~estimated guaranty fund assessment expense recorded~~previously-disclosed value creation plan. These factors were partially offset by an increase in commissions for brokers related to ~~support~~ the ~~policyholder obligations~~individual Medicare Advantage membership growth during the 2023 Annual Election Period, or AEP, and the Open Enrollment Period, or OEP, as well as the favorable impact to revenues in the 2022 quarter as a result of Penn Treaty (an unaffiliated long-term care insurance company). The non-deductible health insurance industry fee impacted the operating cost ratio by 170 basis points in both the 2016 quarter and 2016 period.sequestration relief.

Table of Contents

Depreciation and Amortization

Depreciation and amortization ~~for~~increased $16 million, or 9.4%, from $170 million in the ~~2017~~2022 quarter ~~totaled $94~~to $186 million ~~compared~~in the 2023 quarter primarily due to ~~$86 million for the 2016 quarter. For the 2017 period, depreciation and amortization totaled $278 million compared to $263 million for the 2016 period.~~capital expenditures.

Interest Expense

Interest expense ~~for~~increased $23 million, or 25.6%, from $90 million in the ~~2017~~2022 quarter ~~totaled $59~~to $113 million ~~compared to $47 million for~~in the ~~2016~~2023 quarter ~~and totaled $166 million for the 2017 period compared to $141 million for the 2016 period. The increase was~~ due to higher rates on the ~~issuance of $1 billion of senior notes in March 2017.~~lower average debt balances.

Income Taxes

~~Our~~The effective ~~tax rate during the 2017 quarter was 37.5% compared to the effective tax rate of 50.1% in the 2016 quarter. For the 2017 period our effective~~income tax rate was ~~35.9% compared to the effective tax rate of 50.2%~~22.5% and 23.5% for ~~the 2016 period. These decreases are primarily due to the 2017 temporary suspension of the non-deductible health insurance~~

~~industry fee as well as previously non-deductible transaction costs that, as a result of termination of the Merger Agreement, became deductible for tax purposes and were recorded as such in~~ the three months ended March 31, ~~2017.~~2023, and 2022, respectively. The year-over-year decrease in the effective income tax rate is primarily due to the recognition of a non-taxable gain in the 2023 quarter.

~~Retail~~

Table of Contents

Insurance Segment


	March 31,		Change
	2023	2022	Members	%
Membership:
Individual Medicare Advantage	5,153,000	4,538,200	614,800	13.5	%
Group Medicare Advantage	511,200	562,200	(51,000)	(9.1)	%
Medicare stand-alone PDP	2,956,300	3,607,000	(650,700)	(18.0)	%
Total Medicare	8,620,500	8,707,400	(86,900)	(1.0)	%
Medicare Supplement	294,000	318,400	(24,400)	(7.7)	%
Commercial fully-insured	522,600	624,400	(101,800)	(16.3)	%
Medicaid and other	1,371,500	1,010,300	361,200	35.8	%
Military	5,930,700	6,027,500	(96,800)	(1.6)	%
Commercial ASO	414,800	451,800	(37,000)	(8.2)	%
Total Medical Membership	17,154,100	17,139,800	14,300	0.1	%
Total Specialty Membership (a)	5,114,700	5,182,600	(67,900)	(1.3)	%

(a) We provide a full range of insured specialty products including dental, vision, and life insurance benefits marketed to individuals and groups. Members included in these products may not be unique to each product since members have the ability to enroll in a medical product and one or more specialty products.



								Change
	Three months ended March 31,						Three months ended March 31, 2023 vs 2022
	2023			2022				$		%
	($ in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage	$	19,809		$	17,052			$	2,757	16.2	%
Group Medicare Advantage	1,765			1,875				(110)		(5.9)	%
Medicare stand-alone PDP	616			639				(23)		(3.6)	%
Total Medicare	22,190			19,566				2,624		13.4	%
Commercial fully-insured	1,018			1,140				(122)		(10.7)	%
Specialty benefits	254			261				(7)		(2.7)	%
Medicare Supplement	179			182				(3)		(1.6)	%
Medicaid and other	1,909			1,554				355		22.8	%
Total premiums revenue	25,550			22,703				2,847		12.5	%
Commercial ASO	71			77				(6)		(7.8)	%
Military and other	171			127				44		34.6	%
Services revenue	242			204				38		18.6	%
Total premiums and services revenue	$	25,792		$	22,907			$	2,885	12.6	%
Income from operations	$	1,327		$	996			$	331	33.2	%
Benefit ratio	86.1		%	86.9		%				(0.8)	%
Operating cost ratio	9.4		%	9.1		%				0.3	%

Table of Contents

September 30, Change
2017 2016 Members Percentage
Membership:
Medical membership:
Individual Medicare Advantage 2,849,400
2,831,700
17,700
0.6 %
Group Medicare Advantage 438,400
353,900
84,500
23.9 %
Medicare stand-alone PDP 5,290,900
4,913,400
377,500
7.7 %
Total Retail Medicare 8,578,700
8,099,000
479,700
5.9 %
State-based Medicaid 363,400
390,100
(26,700 ) (6.8 )%
Medicare Supplement 234,900
217,100
17,800
8.2 %
Total Retail medical members 9,177,000
8,706,200
470,800
5.4 %
Income from operations

For the three months ended September 30, Change
2017 2016 Dollars Percentage
(in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage $ 8,077
$ 7,977
$ 100
1.3 %
Group Medicare Advantage 1,272
1,067
205
19.2 %
Medicare stand-alone PDP 921
1,004
(83 ) (8.3 )%
Total Retail Medicare 10,270
10,048
222
2.2 %
State-based Medicaid 630
652
(22 ) (3.4 )%
Medicare Supplement 121
109
12
11.0 %
Total premiums 11,021
10,809
212
2.0 %
Services 2
2
—
— %
Total premiums and services revenue $ 11,023
$ 10,811
$ 212
2.0 %
Income before income taxes $ 610
$ 608
$ 2
0.3 %
Benefit ratio 84.3 % 83.6 % 0.7 %
Operating cost ratio 9.8 % 10.6 % (0.8 )%

For the nine months ended
September 30, Change
2017 2016 Dollars Percentage
(in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage $ 24,735
$ 24,054
$ 681
2.8 %
Group Medicare Advantage 3,867
3,229
638
19.8 %
Medicare stand-alone PDP 2,787
3,058
(271 ) (8.9 )%
Total Retail Medicare 31,389
30,341
1,048
3.5 %
State-based Medicaid 1,954
1,960
(6 ) (0.3 )%
Medicare Supplement 357
319
38
11.9 %
Total premiums 33,700
32,620
1,080
3.3 %
Services 6
5
1
20.0 %
Total premiums and services revenue $ 33,706
$ 32,625
$ 1,081
3.3 %
Income before income taxes $ 1,587
$ 1,263
$ 324
25.7 %
Benefit ratio 86.1 % 85.8 % 0.3 %
Operating cost ratio 8.9 % 10.1 % (1.2 )%

~~Pretax Results~~

~~Retail~~Insurance segment ~~pretax~~ income ~~of $610 million in the 2017 quarter was relatively unchanged~~ from ~~$608 million in the 2016 quarter, reflecting the year-over-year improvement in the operating cost ratio being substantially offset by the increase in the benefit ratio. Retail segment pretax income~~operations increased ~~$324 million,~~$0.3 billion, or ~~25.7%~~33.2%, ~~to $1.6~~from $1.0 billion in the ~~2017 period from~~2022 quarter to $1.3 billion in the ~~2016 period,~~2023 quarter primarily due to the ~~year-over-year improvement in earnings for our Medicare Advantage business.~~same factors impacting the segment's lower benefit ratio offset by the segment's higher operating cost ratio as more fully described below.

Enrollment

Individual Medicare Advantage membership increased ~~17,700~~614,800 members, or ~~0.6%~~13.5%, from ~~September 30, 2016~~March 31, 2022 to September 30, 2017 reflecting net membership additions for Medicare beneficiaries including the effect of market and product exits in 2017. We decided certain markets and/or products were not meeting long term strategic and financial objectives. Additionally, membership growth was mutedMarch 31, 2023 primarily due to ~~competitive actions including the uncertainty~~membership additions associated with the ~~then-pending Merger transaction during last year's~~most recent Annual Election ~~Period.~~Period, or AEP. The year-over-year growth was further impacted by continued enrollment resulting from special elections, age-ins, and Dual Eligible Special Need Plans, or D-SNP, membership. Individual Medicare Advantage membership includes 782,100 D-SNP members as of March 31, 2023, a net increase of 141,500, or 22.1%, from 640,600 as of March 31, 2022.

Group Medicare Advantage membership ~~increased 84,500,~~decreased 51,000 members, or ~~23.9%~~9.1%, from ~~September 30, 2016~~March 31, 2022 to ~~September 30, 2017~~March 31, 2023 reflecting the ~~addition~~net loss of acertain large ~~account~~accounts partially offset by continued growth in ~~January 2017.~~small group accounts.

Medicare stand-alone PDP membership ~~increased 377,500~~decreased 650,700 members, or ~~7.7%~~18.0%, from ~~September 30, 2016~~March 31, 2022 to ~~September 30, 2017~~March 31, 2023 primarily due to continued intensified competition for Medicare stand-alone PDP offerings.

Medicaid and other membership increased 361,200 members, or 35.8%, from March 31, 2022 to March 31, 2023 reflecting ~~net~~the impact of membership additions ~~primarily for our Humana-Walmart plan offering, for~~associated with the ~~2017 plan year.~~implementation of the Louisiana and Ohio contracts effective January 2023 and February 2023, respectively.

~~State-based Medicaid~~Commercial fully-insured medical membership decreased ~~26,700~~101,800 members, or ~~6.8%~~16.3%, from ~~September 30, 2016~~March 31, 2022 to ~~September 30, 2017,~~March 31, 2023 and commercial ASO medical membership decreased 37,000 members, or 8.2%, from March 31, 2022 to March 31, 2023. These decreases reflect our planned exit of the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. The exit from this line of business will be phased over the next 18 to 24 months.

Military membership decreased 96,800 members, or 1.6%, from March 31, 2022 to March 31, 2023. Membership includes military service members, retirees, and their families to whom we are providing healthcare services under the current TRICARE East Region contract.

Specialty membership decreased 67,900 members, or 1.3%, from March 31, 2022 to March 31, 2023 primarily ~~driven by lower~~due to the loss of dental and vision groups cross-sold with medical, as reflected in the loss of group fully-insured commercial medical membership ~~associated with our Florida contracts resulting from network realignments.~~above.

Premiums Revenue

~~Retail~~Insurance segment premiums revenue increased ~~$212 million,~~$2.8 billion, or ~~2.0%~~12.5%, from $22.7 billion in the ~~2016~~2022 quarter to $25.6 billion in the ~~2017~~2023 quarter ~~and increased $1.1 billion, or 3.3%, from the 2016 period to the 2017 period. These increases~~ primarily ~~were~~ due to individual Medicare Advantage and state-based contracts membership growth and ~~increased per-member premiums for certain businesses within the segment. Average group and~~higher per member individual Medicare Advantage ~~membership increased 3.2% for the 2017~~

quarter and 3.5% for the 2017 period. Average membership is calculated by summing the ending membership for each month in a period and dividing the result by the number of months in a period. Premiums revenue reflects changes in membership and average per-member premiums. Items impacting average per-member premiums include changes in premium rates as well as changes in the geographic mix of membership, the mix of product offerings, and the mix of benefit plans selected by our membership.

~~Benefits Expense~~

The Retail segment benefit ratio increased 70 basis points from 83.6% in the 2016 quarter to 84.3% in the 2017 quarter, and increased 30 basis points from 85.8% in the 2016 period to 86.1% in the 2017 period. These increases primarily were due to the impact of the temporary suspension of the health insurance industry fee for calendar year 2017 which was contemplated in the pricing and benefit design of our products, margin compression associated with the competitive environment in the group Medicare Advantage business and lower favorable prior-period medical claims reserve development. These increasesfactors were partially offset by the ~~impact~~phase-out of ~~planned exits from certain Medicare Advantage markets that carried a higher benefit ratio than other markets~~COVID-19 sequestration relief in 2022, as well as ~~lower than expected~~the year-over-year decline in membership associated with group commercial medical, ~~costs as compared to the assumptions used~~group Medicare Advantage and stand-alone PDP products.

Services Revenue

Insurance segment services revenue increased $38 million, or 18.6%, from $204 million in the ~~pricing~~2022 quarter to $242 million in the 2023 quarter.

Table of ~~our~~Contents

Benefits Expense

The Insurance segment benefit ratio decreased 80 basis points from 86.9% for the 2022 quarter to 86.1% for the 2023 quarter primarily due to increased individual Medicare Advantage ~~business.~~

~~The Retail segment’s benefits expense for~~premium yield, lower COVID-19 inpatient utilization in the ~~2017~~2023 quarter, ~~included $52 million~~and the corresponding decrease in ~~favorable prior-period medical claims reserve development versus $80 million in~~average unit cost given the additional 20% payment on these admissions during the Public Health Emergency, as well as higher favorable prior-period medical claims reserve development in the ~~2016~~2023 quarter. For the 2017 period, the Retail segment's benefit expense includes the beneficial effect of $339 million in favorable prior-period reserve development versus $379 million in the 2016 period. Prior-period medical claims reserve development decreased the Retail segment benefit ratio by approximately 50 basis points in the 2017 quarter versus approximately 70 basis points in the 2016 quarter. Favorable prior-period reserve development decreased the benefit ratio by approximately 100 basis points in the 2017 period versus approximately 120 basis points in the 2016 period.

~~Operating Costs~~

The Retail segment operating cost ratio of 9.8% for the 2017 quarter decreased 80 basis points from 10.6% for the 2016 quarter. The Retail segment operating cost ratio of 8.9% for the 2017 period decreased 120 basis points from 10.1% for the 2016 period. These ~~decreases primarily~~factors were ~~due to the temporary suspension of the health insurance industry fee for calendar year 2017,~~ partially offset by the increase in employee compensation costs resulting from the continued strong performance. The non-deductible health insurance industry fee impacted the operating cost ratio by 170 basis points in each of the 2016 quarter and the 2016 period.

~~Group and Specialty Segment~~

September 30, Change
2017 2016 Members Percentage
Membership:
Medical membership:
Fully-insured commercial group 1,098,800
1,131,500
(32,700 ) (2.9 )%
ASO 445,700
570,300
(124,600 ) (21.8 )%
Military services 3,099,000

3,080,900

18,100

0.6 %
Total group and specialty medical members 4,643,500
4,782,700
(139,200 ) (2.9 )%
Specialty membership (a) 6,934,000
6,955,200
(21,200 ) (0.3 )%


~~(a)~~	Specialty products include dental, vision, voluntary benefit products and other supplemental health and financial protection products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.

For the three months ended September 30, Change
2017 2016 Dollars Percentage
(in millions)
Premiums and Services Revenue:
Premiums:
Fully-insured commercial group $ 1,370
$ 1,350
$ 20
1.5 %
Group specialty 331
318
13
4.1 %
Military services —
2
(2 ) (100.0 )%
Total premiums 1,701
1,670
31
1.9 %
Services 140
147
(7 ) (4.8 )%
Total premiums and services revenue $ 1,841
$ 1,817
$ 24
1.3 %
Income before income taxes $ 93
$ 37
$ 56
151.4 %
Benefit ratio 79.6 % 81.0 % (1.4 )%
Operating cost ratio 20.9 % 23.1 % (2.2 )%

For the nine months ended
September 30, Change
2017 2016 Dollars Percentage
(in millions)
Premiums and Services Revenue:
Premiums:
Fully-insured commercial group $ 4,098
$ 4,044
$ 54
1.3 %
Group specialty 976
957
19
2.0 %
Military services —
12
(12 ) (100.0 )%
Total premiums 5,074
5,013
61
1.2 %
Services 444
500
(56 ) (11.2 )%
Total premiums and services revenue $ 5,518
$ 5,513
$ 5
0.1 %
Income before income taxes $ 365
$ 333
$ 32
9.6 %
Benefit ratio 77.9 % 77.3 % 0.6 %
Operating cost ratio 21.3 % 23.1 % (1.8 )%

~~Pretax Results~~

~~Group and Specialty segment pretax income was $93 million~~investments in the ~~2017~~benefit design of our products for 2023. Further, the 2023 quarter ~~an increase~~ratio continues to reflect a shift in line of ~~$56~~business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio.

The Insurance segment benefits expense included $522 million ~~or 151.4%, from $37 million in the 2016 quarter. This increase primarily reflects the impact~~ of higher pretax earnings associated with our fully-insured commercial medical products. The Group and Specialty segment pretax income was $365 million in the 2017 period, an increase of $32 million from $333 million in the 2016 period. The increase primarily reflects the impact of higher pretax earnings associated with our fully-insured commercial medical products, partially offset by the impact of the timing of revenues under our TRICARE contract primarily relating to medical cost trend incentives and amounts for additional services requested under the contract.

~~Enrollment~~

Fully-insured commercial group medical membership decreased 32,700 members, or 2.9%, from September 30, 2016 to September 30, 2017 reflecting lower membership in small group accounts due in part to more small group accounts selecting ASO products in 2017.

Group ASO commercial medical membership decreased 124,600 members, or 21.8%, from September 30, 2016 to September 30, 2017 primarily due to the loss of certain large group accounts as a result of continued discipline in pricing of services for self-funded accounts amid a highly competitive environment, partially offset by more small group accounts selecting ASO products in 2017.

Specialty membership decreased 21,200 members, or 0.3%, from September 30, 2016 to September 30, 2017 primarily due to declines in other supplemental benefits membership, as well as a decline in dental ASO membership due to terminations of several large group accounts. Other supplemental benefits include life, disability, and fixed benefit products including cancer and critical illness policies.

~~Premiums Revenue~~

Group and Specialty segment premiums increased $31 million, or 1.9%, from the 2016 quarter to $1.7 billion for the 2017 quarter and increased $61 million, or 1.2%, from the 2016 period to $5.1 billion for the 2017 period. These increases primarily were due to an increase in group fully-insured commercial medical per-member premiums, partially offset by a decline in average group fully-insured commercial medical membership.

~~Services Revenue~~

Group and Specialty segment services revenue was relatively unchanged for the 2017 quarter, decreasing $7 million, or 4.8%, from the 2016 quarter. The Group and Specialty segment service revenue decreased $56 million, or 11.2%, from the 2016 period to $444 million for the 2017 period, primarily due to a decline in revenue in our group ASO commercial medical business mainly due to membership declines as well as due to the timing of revenue under our TRICARE contract.

~~Benefits Expense~~

~~The Group and Specialty segment benefit ratio decreased 140 basis points from 81.0% in the 2016 quarter to 79.6% in the 2017 quarter primarily reflecting~~ favorable ~~utilization in the fully-insured commercial medical business and higher favorable~~ prior-period medical claims reserve development ~~partially offset by the impact of the temporary suspension of the health insurance industry fee for calendar year 2017 which was contemplated~~ in the ~~pricing~~2023 quarter and $360 million of our products. The Group and Specialty segment benefit ratio increased 60 basis points from 77.3% in the 2016 period to 77.9% in the 2017 period primarily due to the impact of the temporary suspension of the health insurance industry fee for calendar year 2017 which was contemplated in the pricing of our products, partially offset by lower utilization for the fully-insured commercial medical business in the 2017 period.

~~The Group and Specialty segment benefits expense included $13 million in~~ favorable prior-period medical claims reserve development in the ~~2017 quarter versus favorable prior-period medical claims reserve development of $3 million in the 2016~~2022 quarter. ~~This favorable prior-period~~Prior-period medical claims reserve development decreased the ~~Group and Specialty~~Insurance segment benefit ratio by approximately 80200 basis points in the ~~2017~~2023 quarter and decreased the benefit ratio by 20 basis points in the 2016 quarter. The Group and Specialty segment’s benefits expense included the beneficial effect of a favorable prior-period medical claims reserve development of $44 million in the 2017 period versus $41 million in the 2016 period. This favorable prior-period medical claims reserve development decreased the Group and SpecialtyInsurance segment benefit ratio by approximately 90160 basis points in the ~~2017 period and 80 basis points in the 2016 period.~~2022 quarter.

Operating Costs

The ~~Group and Specialty~~Insurance segment operating cost ratio ~~of 20.9% for the 2017 quarter decreased 220~~increased 30 basis points from ~~23.1%~~9.1% for the ~~2016 quarter. For the 2017 period, the Group and Specialty segment operating cost ratio of 21.3% decreased 180 basis points from 23.1%~~2022 quarter to 9.4% for the ~~2016 period. These decreases~~2023 quarter primarily ~~were~~ due to ~~the temporary suspension of the health insurance industry fee for calendar year 2017 as well as operating cost efficiencies, partially offset by~~ an increase in employee compensation costs resulting from the continued strong performance. The non-deductible health insurance industry fee impacted the operating cost ratio by 150 basis points in both the 2016 quarter and period.

~~Healthcare Services Segment~~

For the three months ended September 30, Change
2017 2016 Dollars Percentage
(in millions)
Revenues:
Services:
Clinical care services $ 39
$ 50
$ (11 ) (22.0 )%
Pharmacy solutions 20
8
12
150.0 %
Provider services 21
19
2
10.5 %
Total services revenues 80
77
3
3.9 %
Intersegment revenues:
Pharmacy solutions 5,246
5,562
(316 ) (5.7 )%
Provider services 392
418
(26 ) (6.2 )%
Clinical care services 273

341

(68 )
(19.9 )%
Total intersegment revenues 5,911
6,321
(410 ) (6.5 )%
Total services and intersegment revenues $ 5,991
$ 6,398
$ (407 ) (6.4 )%
Income before income taxes $ 240
$ 297
$ (57 ) (19.2 )%
Operating cost ratio 95.6 % 94.9 % 0.7 %

For the nine months ended
September 30, Change
2017 2016 Dollars Percentage
(in millions)
Revenues:
Services:
Clinical care services $ 135
$ 157
$ (22 ) (14.0 )%
Pharmacy solutions 58
22
36
163.6 %
Provider services 58
58
—
— %
Total services revenues 251
237
14
5.9 %
Intersegment revenues:

Pharmacy solutions 15,581
16,404
(823 ) (5.0 )%
Provider services 1,207
1,263
(56 ) (4.4 )%
Clinical care services 876
998
(122 ) (12.2 )%
Total intersegment revenues 17,664
18,665
(1,001 ) (5.4 )%
Total services and intersegment revenues $ 17,915
$ 18,902
$ (987 ) (5.2 )%
Income before income taxes $ 754
$ 828
$ (74 ) (8.9 )%
Operating cost ratio 95.4 % 95.2 % 0.2 %

~~Pretax Results~~

~~Healthcare Services segment pretax income of $240 million~~commissions for the 2017 quarter decreased by $57 million, or 19.2%, from $297 million in the 2016 quarter. For the 2017 period, the Healthcare Services segment pretax income of $754 million decreased $74 million, or 8.9%, from $828 million in the 2016 period. These decreases primarily were duebrokers related to the ~~impact of~~individual Medicare Advantage membership growth during the ~~optimization process associated with our chronic care management~~

~~programs~~2023 AEP and increases in the operating cost ratio for both the 2017 quarter and period, as well as pressures in our provider services business reflecting lower Medicare rates year-over-year in geographies where our provider assets are primarily located for the 2017 period. The reductions in pharmacy solutions intersegment revenues were offset by similar reductions in operating costs associated with the pharmacy solutions business.

~~Script Volume~~

Humana Pharmacy Solutions script volumes on an adjusted 30-day equivalent basis for Retail, Group and Specialty, and Individual Commercial segment membership increased to approximately 108 million in the 2017 quarter, up 1.2%, versus scripts of approximately 107 million in the 2016 quarter. For the 2017 period, script volumes for Retail, Group and Specialty, and Individual Commercial segment membership increased to approximately 323 million, up 2.1%, versus scripts of approximately 316 million in the 2016 period. These increases primarily reflected growth associated with higher Medicare membership for the 2017 quarter and 2017 period compared to the 2016 quarter and 2016 period, partially offset by the decline in Individual Commercial membership.

~~Services Revenues~~

Services revenues increased $3 million, or 3.9%, from the 2016 quarter to $80 million for the 2017 quarter and increased $14 million, or 5.9%, from the 2016 period to $251 million for the 2017 period primarily due to service revenue growth from our pharmacy solutions business.

~~Intersegment Revenues~~

Intersegment revenues decreased $410 million, or 6.5%, from the 2016 quarter to $5.9 billion for the 2017 quarter and decreased $1.0 billion, or 5.4%, from the 2016 period to $17.7 billion for the 2017 period primarily due to our pharmacy solutions businessOEP, as well as the favorable impact to revenues in the 2022 quarter as a result of the optimization process associated with our chronic care management programs discussed previously, as well as ongoing pressures in our provider services business reflecting lower Medicare rates year-over-year in geographies where our provider assets are primarily located. Our pharmacy solutions business revenues were impacted by improvements in net pharmacy costs driven by our pharmacy benefit manager and an increase in the generic dispensing rate.sequestration relief. These ~~items~~factors were partially offset by ~~higher year-over-year script volume from~~scale efficiencies associate with growth in ~~our~~the individual Medicare Advantage ~~and stand-alone PDP~~ membership ~~partially offset by~~and the impact of lower Individual Commercial membership. Our generic dispensing rate improved to 91.2% and 91.3% during the 2017 quarter and 2017 period, respectively, compared to 90.4% and 90.3% during the 2016 quarter and 2016 period, respectively. The higher generic dispensing rate reduced revenues (and operating costs) for our pharmacy solutions business as generic drugs are generally priced lower than branded drugs.

~~Operating Costs~~

~~The Healthcare Services segment operating cost ratio of 95.6% for the 2017 quarter increased 70 basis points from 94.9% for the 2016 quarter primarily due~~initiatives related to the ~~timing~~previously-disclosed value creation plan.

Table of the optimization process associated with our chronic conditions management programs and the increase in employee compensation costs resulting from the continued strong performance. As we optimize our chronic care management programs, operating cost reductions may lag the associated reduction in revenue, negatively impacting the operating cost ratio. For the 2017 period, the Healthcare Services segment operating cost ratio was relatively unchanged from the 2016 period.Contents

~~Individual Commercial~~CenterWell Segment




								Change
	Three months ended March 31,						Three months ended March 31, 2023 vs 2022
	2023			2022				$		%
	($ in millions)
Revenues:
Services:


Home solutions	$	314		$	726			$	(412)	(56.7)	%
Pharmacy solutions	242			221				21		9.5	%
Provider services	201			113				88		77.9	%
Total services revenue	757			1,060				(303)		(28.6)	%
Intersegment revenues:


Home solutions	314			109				205		188.1	%
Pharmacy solutions	2,615			2,446				169		6.9	%
Provider services	819			748				71		9.5	%
Total intersegment revenues	3,748			3,303				445		13.5	%
Total services and intersegment revenues	$	4,505		$	4,363			$	142	3.3	%
Income from operations	$	330		$	370			$	(40)	(10.8)	%
Operating cost ratio	91.6		%	90.5		%				1.1	%

~~As announced on February 14, 2017, we are exiting our Individual Commercial medical business commencing January 1, 2018.~~

Income from operations

~~Individual Commercial segment pretax~~CenterWell income ~~of $26~~from operations decreased $40 million, ~~for~~or 10.8%, from $370 million in the ~~2017~~2022 quarter ~~increased $24~~to $330 million ~~from~~in the ~~2016~~2023 quarter primarily due to the exit of certain markets in 2017, and per-member premium increases. For the 2017 period, the Individual Commercial segment pretax income of $207 million increased $442 million from the 2016 period, primarily due to the same factors impacting the ~~quarter in addition to the $208 million increase in the premium deficiency reserve recorded in the second quarter of 2016 related to certain of our 2016 policies.~~

Individual commercial medical membership decreased 583,400 members, or 80.3%, from September 30, 2016 to September 30, 2017 reflecting the decline in the number of counties we offered on-exchange coverage and the discontinuance of offering off-exchange products.

The benefit ratio for the Individual Commercial segment was 65.6% and 51.6% for the 2017 quarter and 2017 period, respectively, a significant decrease from 82.4% and 90.9% for the 2016 quarter and 2016 period, respectively. The year-over-year declines primarily resulted from the impact from planned exits in 2017 in certain markets that carried asegment's higher benefit ratio, and per-member premium increases. The 2017 period was also impacted by the effect of the $208 million increase in the 2016 premium deficiency reserve recorded in the second quarter of 2016 related to certain of our 2016 policies.

~~The~~ operating cost ratio ~~for~~offset by the ~~Individual Commercial segment was 21.9%~~segment's increase in revenues as more fully described below.

Services Revenue

CenterWell services revenue decreased $0.3 billion, or 28.6%, from $1.1 billion in the ~~2017~~2022 quarter ~~an increase of 560 basis points from 16.3%~~to $0.8 billion in the ~~2016~~2023 quarterprimarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022.

Intersegment Revenues

CenterWell intersegment revenues increased $0.4 billion, or 13.5%, from $3.3 billion in the 2022 quarter to $3.7 billion in the 2023 quarter primarily due to individual Medicare Advantage membership growth, which led to higher pharmacy revenues, higher revenues associated with growth in the provider business, and greater intersegment revenues associated with the home solutions business as a result of the expansion of the value-based care home model in the 2023 quarter compared to the 2022 quarter.

Operating Costs

The ~~Individual Commercial~~CenterWell segment operating cost ratio ~~of 20.0% for the 2017 period~~ increased ~~340~~110 basis points from ~~16.6%~~90.5% for the 2022 quarter to 91.6% for the 2023 quarter primarily due the divestiture of the 60% ownership of Gentiva Hospice in August 2022, which carried a lower operating cost ratio compared to other businesses within the segment, the expansion of the value-based care model within the home solutions business, which carries a higher ratio compared to the core fee-for-service business, along with growth in the ~~2016 period.~~core fee-for-service business, as well as further investments within the home solutions business to abate the pressures of the current nursing labor environment. These increases ~~are primarily due to the loss of scale efficiency from market exits in 2017~~were partially offset by an improving ratio in the ~~temporary suspension~~provider business.

Table of ~~the health insurance industry fee for calendar year 2017.~~Contents

Liquidity

~~Our~~Historically, our primary sources of cash ~~include~~have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, ~~borrowings,~~ and ~~proceeds from sales of businesses.~~borrowings. Our primary uses of cash ~~include~~historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. ~~Because~~As premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of ~~operating~~ cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of ~~operating~~ cash flows derived from our non-insurance subsidiaries, such as in our ~~Healthcare Services~~CenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).

The effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law impact the timing of our operating cash flows, as we build receivables for each coverage year that are expected to be collected in subsequent coverage years. During the nine months ended September 30, 2017, net collections under the 3Rs associated with prior coverage years were $307 million compared to $319 million during the nine months ended September 30, 2016. The remaining net receivable balance associated with the 3Rs was approximately $173 million at September 30, 2017, including $171 million related to prior coverage years, compared to $456 million at December 31, 2016, neither of which includes any risk corridor receivable. Amounts associated with prior coverage years of $171 million are expected to be collected during the fourth quarter of 2017 and first quarter of 2018. The remaining net receivable balance is primarily related to our Individual Commercial medical business which we are exiting commencing January 1, 2018. Any amounts receivable or payable associated with these risk limiting programs may have an impact on subsidiary liquidity, with any temporary shortfalls funded by the parent company.

For additional information onregarding our liquidity risk, ~~please~~ refer to ~~the section entitled “Risk Factors”~~Part I, Item 1A, "Risk Factors" in our ~~2016~~2022 Form ~~10-K.~~10-K and Part II, Item 1A, "Risk Factors" of this Form 10-Q.

Cash and cash equivalents increased to approximately ~~$9.9~~$13.7 billion at ~~September 30, 2017~~March 31, 2023 from ~~$3.9~~$5.1 billion at December 31, ~~2016.~~2022. The change in cash and cash equivalents for the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2023 and ~~2016~~2022 is summarized as follows:


	Nine Months Ended							Three Months Ended
	2017			2016				2023		2022
	(in millions)							(in millions)
Net cash provided by operating activities	$	6,962		$	4,709		Net cash provided by operating activities	$	6,687	$	302
Net cash used in investing activities	(1,776		)	(534		)	Net cash used in investing activities	(1,292)		(648)
Net cash provided by financing activities	802			23			Net cash provided by financing activities	3,279		1,816
Increase in cash and cash equivalents	$	5,988		$	4,198		Increase in cash and cash equivalents	$	8,674	$	1,470

Cash Flow from Operating Activities

Cash flows provided by operations of $6.7 billion in the 2023 quarter increased $6.4 billion from cash flows provided by operations of $302 million in the 2022 quarter. Our operating cash flows for the ~~2017 period~~2023 quarter were significantly impacted ~~by the receipt of the $1 billion Merger break-up fee, net of related expenses and the portion of taxes paid to date, and~~ by the early receipt of the Medicare premium remittance ~~for October 2017~~ of ~~$3.1~~$6.6 billion in ~~September 2017, as well as for October 2016 of $3.0 billion in September 2016,~~March 2023 because the payment ~~dates of October 1, 2017 and October 1, 2016~~date for April 2023 fell on a weekend. Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), we receive this payment at the end of the previous month. This also resulted in an increase to unearned revenues in our condensed consolidated balance sheet at ~~September 30, 2017. Excluding the Merger termination fee and the timing of the Medicare premium remittances, our~~March 31, 2023. Our operating cash flows for the 2023 quarter were ~~positively~~further negatively impacted by ~~higher earnings and the timing of~~ working capital ~~items.~~items in the quarter compared to the 2022 quarter.

The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. ~~We illustrate these changes with~~Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the ~~following summaries of~~balance sheet date. For additional information regarding our benefits payable and ~~receivables.~~

~~The detail of~~ benefits ~~payable was as follows at September 30, 2017~~expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and ~~December 31, 2016:~~

September 30, 2017 December 31, 2016 2017
Period
Change 2016
Period
Change
(in millions)
IBNR (1) $ 3,308
$ 3,422
$ (114 ) $ (104 )
Reported claims in process (2) 698
654
44
22
Premium deficiency reserve (3) —
—
—
30
Other benefits payable (4) 953
487
466
125
Total benefits payable $ 4,959
$ 4,563
$ 396
$ 73

~~(1)~~

IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date and includes unprocessed claim inventories. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received and processed (i.e. a shorter time span results in a lower IBNR).


~~(2)~~	Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.


~~(3)~~	~~Premium deficiency reserve for our Individual Commercial medical business compliant with the Health Care Reform Law associated with the 2016 coverage year.~~


~~(4)~~	~~Other benefits payable primarily include amounts owed to providers under capitated and risk sharing arrangements.~~

~~The increase~~Supplementary Data" in benefits payable from December 31, 2016 to September 30, 2017 primarily was due to an increase in the amounts owed to providers under the capitated and risk sharing arrangements. This was partially offset by a decrease in IBNR primarily driven by declines in individual commercial medical membership in the 2017 period, partially offset by an increase in group Medicare Advantage membership. The increase in benefits payable from December 31, 2015 to September 30, 2016 largely was due to an increase in the amounts owed to providers under the capitated and risk sharing arrangements, an increase in the premium deficiency reserve associated with our individual commercial medical products, and an increase in the amount of processed but unpaid claims, which fluctuate due to month-end cutoff. These items were partially offset by a decrease in IBNR primarily driven by declines in group Medicare Advantage and individual commercial medical membership in the 2016 period, partially offset by an increase in individual Medicare Advantage membership.2022 Form 10-K.

The detail of total net receivables ~~was as follows~~ at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016:~~2022 and reconciliation to cash flow for the three months ended March 31, 2023 and 2022 was as follows:

Table of Contents


	September 30, 2017			December 31, 2016			2017 Period Change			2016 Period Change				March 31, 2023		December 31, 2022		2023 Quarter Change		2022 Quarter Change
	(in millions)													(in millions)
Medicare	$	494		$	787		$	(293	)	$	(259	)	Medicare	$	2,658	$	1,260	$	1,398	$	1,358
Commercial and other	441			579			(138		)	(100		)	Commercial and other	449		383		66		(16)
Military services	76			32			44			(27		)
Allowance for doubtful accounts	(89		)	(118		)	29			(10		)
Military													Military	69		101		(32)		4
Allowances													Allowances	(69)		(70)		1		14
Total net receivables	$	922		$	1,280		$	(358	)	$	(396	)	Total net receivables	$	3,107	$	1,674	$	1,433	$	1,360

The changes in Medicare receivables for both the ~~2017 period~~2023 quarter and the ~~2016 period~~2022 quarter reflect individual Medicare Advantage membership growth and the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the mid-year and final settlements with CMS in the second and third quarter.

Many provisions of the Health Care Reform Law became effective in 2014, including the commercial risk adjustment, risk corridor, and reinsurance provisions as well as the non-deductible health insurance industry fee. As discussed previously, the timing of payments and receipts associated with these provisions impact our operating cash flows as we build receivables for each coverage year that are expected to be collected in subsequent coverage years. During the 2017 period, we received net collections of $307 million for the commercial 3Rs associated with prior coverage years as compared to net collections of $319 million in the 2016 period. The net receivable balance associated with the 3Rs was approximately $173 million at September 30, 2017 and $456 million at December 31, 2016, including certain amounts recorded in receivables in the table above. In 2017, we will not pay the federal government for the annual health insurance industry fee due to the temporary one year suspension as compared to our payment of $916 million in the third quarter of 2016. The Consolidated Appropriations Act, 2016, enacted on December 18, 2015, included a one-time one year suspension in 2017 of the health insurer fee.

Cash Flow from Investing Activities

~~We reinvested a portion~~During the 2023 quarter, we acquired various businesses totaling to approximately $73 million, net of ~~our operating~~ cash ~~flows in investment securities, primarily investment-grade fixed income securities, totaling $1.4 billion in~~received.

During the ~~2017 period~~2022 quarter, we acquired various health and ~~$132~~wellness related businesses for cash consideration of approximately $74 million, ~~in the 2016 period.~~net of cash received.

Our ongoing capital expenditures primarily relate to our information technology initiatives, ~~as well as~~ support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were ~~$376~~$223 million in the ~~2017 period~~2023 quarter and ~~$395~~$295 million in the ~~2016 period.~~2022 quarter.

Net purchases of investment securities were $1.0 billion in the 2023 quarter and net purchases of investment securities were $279 million in the 2022 quarter.

Cash Flow from Financing Activities

Receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than ~~claims~~claim payments by ~~$1.9~~$3.03 billion ~~during~~and $2.48 billion in the ~~2017 period~~2023 and higher than claims payments by $404 million during the 2016 period. Our net payable for CMS subsidies and brand name prescription drug discounts was $1.1 billion at September 30, 2017 compared to a net receivable of $1.6 billion at September 30, 2016 and $873 million at December 31, 2016. Refer to Note 6 to the condensed consolidated financial statements included in this report.2022 quarters, respectively.

Under our administrative services only TRICARE ~~South Region contract, reimbursements from the federal government exceeded~~contracts, health care ~~cost~~costs payments for which we do not assume risk exceeded reimbursements from the federal government by ~~$22~~$29 million and $2 million in the ~~2017 period~~2023 and ~~by $8~~2022 quarters, respectively.

Net repayments from the issuance of commercial paper were $177 million in the ~~2016 period.~~

~~Claims payments associated with cost sharing provisions~~2023 quarter and net repayments from the issuance of commercial paper were $265 million in the ~~Health Care Reform Law for which we do not assume risk were~~ ~~$41 million higher than reimbursements from HHS~~2022 quarter. The maximum principal amount outstanding at any one time during the ~~2017 period~~2023 quarter was $626 million.

In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and ~~$62~~$750 million ~~higher than reimbursements from HHS~~of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

In March 2022, we issued $750 million of 3.700% unsecured senior notes due March 23, 2029. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $744 million.

Table of Contents

In March 2023, we entered into a Rule 10b5-1 Repurchase Plan, or the Plan, to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the ~~2016 period.~~

~~Under a share repurchase plan authorized by the Board of Directors,~~Plan period beginning on March 13, 2023 and ending on June 15, 2023. At March 31, 2023, we repurchased ~~7.63~~$61 million, for cash totaling approximately $60 million.

We repurchased common shares for ~~$1.7~~$67 million and $1.0 billion in the ~~2017 period, including $1.5 billion under the February 2017 accelerated stock repurchase plan. There were no share repurchases~~2023 quarter and 2022 quarter, respectively, under share repurchase plans authorized by the Board of ~~Directors in the 2016 period due to the restrictions of the Merger Agreement.~~Directors. We also acquired common shares in connection with employee stock plans for ~~an aggregate cost of $79~~$27 million and $24 million in the ~~2017 period~~2023 quarter and ~~$75 million in the 2016 period.~~

In March 2017, we issued $600 million of 3.95% senior notes due March 15, 2027 and $400 million of 4.80% senior notes due March 15, 2047. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid as of March 31, 2017, were $991 million. We intend to use the net proceeds for general corporate purposes.

Net repayments of commercial paper were $153 million in the 2017 period and $1 million in the 2016 period. The maximum principal amount outstanding at any one time during the 2017 period was $500 million.2022 quarter, respectively.

We paid dividends to stockholders of ~~$162~~$100 million during the ~~2017 period~~2023 quarter and ~~$133~~$91 million during the ~~2016 period, as discussed further below.~~2022 quarter.

The remainder of the cash used in or provided by financing activities in 2023 and 2022 primarily resulted from the change in book overdraft.

Future Sources and Uses of Liquidity

Dividends

For ~~a detailed discussion of~~additional information regarding our dividends to stockholders, ~~please~~ refer to Note 1110 to the ~~condensed consolidated financial statements.~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Stock Repurchases

For ~~a detailed discussion of~~additional information regarding stock repurchases, ~~please~~ refer to Note 1110 to the ~~condensed consolidated financial statements.~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Debt

For ~~a detailed discussion of our~~additional information regarding debt, including our senior notes, term loans, revolving credit ~~agreement and~~agreements, commercial paper program ~~please~~and other short-term borrowings, refer to Note 1312 to the ~~condensed consolidated financial statements.~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

~~Divestitures~~Divestiture

On ~~November 6, 2017,~~August 11, 2022, we ~~entered into~~completed the sale of a ~~definitive agreement~~60% interest in Gentiva Hospice to ~~sell~~CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the ~~stock~~sale we recognized a pre-tax gain, net of ~~our wholly-owned subsidiary, KMG America Corporation, or KMG,~~transaction costs, of $237 million.

For additional information regarding the divestiture, refer to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG’s subsidiary, Kanawha Insurance Company, or KIC, includes our closed block of non-strategic commercial long-term care insurance policies. We will fund the transaction with approximately $203 million of parent company cash contributed into KMG, subject to customary adjustments, in additionNote 3 to the ~~transfer~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of ~~approximately $150 million of statutory capital with the sale.~~

this Form 10-Q.

Liquidity Requirements

We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.

Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at ~~September 30, 2017~~March 31, 2023 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa3 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to ~~$750~~

Table of Contents

$250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $2less than $1 million, up to a maximum 100 basis points, or annual interest expense by $8$3 million.

In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were ~~$2.3 billion~~$909 million at ~~September 30, 2017~~March 31, 2023 compared to ~~$2.0 billion~~$934 million at December 31, ~~2016.~~2022. This ~~increase~~decrease primarily reflects ~~the receipt of $1.4 billion of subsidiary dividends, the receipt~~common stock repurchases, repayment of the ~~Merger termination fee, net~~delayed draw term loan, repayment of ~~related expenses,~~maturing senior notes, capital expenditures, repayment of borrowings under the commercial paper program, capital contributions to certain subsidiaries, cash dividends to shareholders and ~~the~~acquisitions, partially offset by net proceeds ~~associated with~~from the issuance of senior notes ~~in March 2017, partially offset by~~and the ~~payment~~sale of $1.7 billion for our share repurchase program, the capital contribution of $535 million to our long-term care subsidiary, as described below, dividends, capital expenditures and other insignificant items. investment securities.Our use of operating cash derived from our non-insurance subsidiaries, such as our ~~Healthcare Services~~CenterWell segment, is generally not restricted by departments of insurance (or comparable state ~~regulator)~~regulators).

Our parent company funded a subsidiary capital contribution of approximately $535 million in the first quarter of 2017 for reserve strengthening associated with our closed block of long-term care insurance policies.

The annual health insurance industry fee has been suspended for calendar year 2017, but is scheduled to resume in calendar year 2018. In September 2016, we paid the federal government $916 million for our portion of the annual health insurance industry fee attributed to calendar year 2016 in accordance with the Health Care Reform Law. This fee is not deductible for tax purposes. Each year on January 1, except for 2017, we record a liability for this fee in trade accounts payable and accrued expenses which we carry until the fee is paid. We record a corresponding deferred cost in other current assets in our condensed consolidated financial statements which is amortized ratably to expense over the calendar year. Amortization of the deferred cost resulted in operating cost expense of approximately $231 million and $687 million for the three and nine months ended September 30, 2016, respectively, resulting from the amortization of the 2016 annual health insurance industry fee.

Regulatory Requirements

Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required. ~~Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.~~

Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of ~~June 30, 2017,~~December 31, 2022, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately ~~$7.3~~$11.3 billion, which exceeded aggregate minimum regulatory requirements of ~~$4.8~~$8.4 billion. ~~Subsidiary~~The amount of ordinary dividends ~~are subject~~that may be paid to our parent company in 2023 is approximately $1.8 billion in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state regulatory ~~approval,~~requirements, the ~~amount~~level of excess statutory capital and ~~timing of which could be reduced or delayed. The amount of~~surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends paid to our parent company ~~was~~were approximately ~~$1.4~~$1.3 billion ~~during the nine months ended September 30, 2017 compared to $663 million during the nine months ended September 30, 2016.~~in 2022.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.

Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA at ~~September 30, 2017.~~March 31, 2023. Our net unrealized position increased ~~$198~~$248 million from a net unrealized loss position of ~~$28 million~~$1.7 billion at December 31, ~~2016~~2022 to a net unrealized ~~gain~~loss position of ~~$170 million~~$1.4 billion at ~~September 30, 2017.~~March 31, 2023. At ~~September 30, 2017,~~March 31, 2023, we had gross unrealized losses of ~~$82 million~~$1.5 billion on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. There ~~were~~were no material ~~other-than-temporary impairments during~~credit allowances during the ~~nine~~three months ended ~~September 30, 2017.~~March 31, 2023. While we believe that these ~~impairments are temporary~~securities in an unrealized loss will recover in value over time and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or ~~other-than-temporary impairments~~credit allowances may be recorded in future periods.

Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately ~~3.4~~3.2 years as of ~~September 30, 2017~~March 31, 2023 and ~~approximately 4.4 years as of~~ December 31, ~~2016.~~2022. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately ~~$700~~$656 million at ~~September 30, 2017.~~March 31, 2023.

Item 4. Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended ~~September 30, 2017.~~March 31, 2023.

Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended ~~September 30, 2017~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

T a ble of Contents

Part II. Other Information

Item 1. Legal Proceedings

For ~~a description of the~~additional information regarding legal proceedings pending against us and certain other pending or threatened litigation, investigations or other matters, ~~see~~refer to “Legal Proceedings and Certain Regulatory Matters” in Note 1413 to the ~~condensed consolidated financial statements beginning on page 29~~unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Item 1A. Risk Factors

There have been no changes to the risk factors included in our ~~2016~~2022 Form ~~10-K, other than as follows:~~10-K.

The divestiture of our subsidiary, KMG America Corporation, is subject to various closing conditions, including various regulatory approvals and customary closing conditions, as well as other uncertainties, and there can be no assurances as to whether and when it may be completed.

On November 6, 2017, we entered into a definitive agreement to sell the stock of our wholly-owned subsidiary, KMG America Corporation, or KMG, to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG’s subsidiary, Kanawha Insurance Company, or KIC, includes our closed block of non-strategic commercial long-term care insurance policies that serves approximately 30,100 policyholders. Consummation of the divestiture involves certain risks, including, among other things, the timing to consummate the divestiture, the risk that a condition to closing of the divestiture may not be satisfied, the risk that required regulatory approvals for the divestiture are not obtained, are delayed or are subject to conditions that are not anticipated, the risk that we may not recognize all or a portion of the expected tax benefits from the divestiture, and the risk of indemnification exposure under the contractual agreements to effect the divestiture.


~~Item 2:~~	~~Unregistered Sales of Equity Securities and Use of Proceeds~~


~~(a)~~	~~None.~~


~~(b)~~	~~N/A~~


~~(c)~~	The following table provides information about our purchases of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the three months ended September 30, 2017:

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)None.

(b)N/A

(c)The following table provides information about our purchases of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the three months ended March 31, 2023:


Period	Total Number of Shares Purchased (1)(2)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2)	Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) (2)
January 2023	—	$	—	—	$	3,000,000,000
February 2023	—	—		—	3,000,000,000
March 2023	134,490	495.68		134,490	2,933,335,748
Total	134,490	$	495.68	134,490

(1)On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. Our remaining repurchase authorization was $2.8 billion as of April 25, 2023.

(2)Excludes 52,434 shares repurchased in connection with employee stock plans.

Period Total Number
of Shares
Purchased (1)(2) Average
Price Paid
per Share (3) Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs (1)(2) Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs (1)
July 2017 —
$ —
—
$ 1,050,000,093
August 2017 953,235
253.02
953,235
721,003,128
September 2017 844,568
249.56
844,568
510,251,912
Total 1,797,803
$ 249.97
1,797,803

~~(1)~~

On February 14, 2017, we announced that the Board had approved a new authorization for share repurchases of up to $2.25 billion of our common stock exclusive of shares repurchased in connection with employee stock plans, expiring on December 31, 2017. Under this new authorization, we entered into a $1.5 billion accelerated share repurchase program in the first quarter of 2017. On August 28, 2017, we completed the final settlement of our accelerated share repurchase program. Our remaining repurchase authorization was approximately $239 million as of November 3, 2017.


~~(2)~~	Includes 0.84 million shares received in August 2017 upon settlement of an accelerated repurchase program for which no cash was paid during the period and excludes 0.37 million shares repurchased in connection with employee stock plans.


~~(3)~~	Excludes the impact of the 0.84 million shares received in August 2017 upon settlement of an accelerated repurchase program which were determined by the average daily volume weighted-average share price of our common stock during the term of the ASR Agreement of $224.81.


~~Item 3:~~	~~Defaults Upon Senior Securities~~

Item 3. Defaults Upon Senior Securities

None.


~~Item 4:~~	~~Mine Safety Disclosures~~

Item 4. Mine Safety Disclosures

Not applicable.


~~Item 5:~~	~~Other Information~~

Item 5. Other Information

None.

T a ble of Contents

Item 6: Exhibits


~~Item 6:~~			~~Exhibits~~


3(i)	Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, and the correction of March 23, 1992 (incorporated herein by reference to Exhibit 4(i) to Humana Inc.’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Reg. No. 33-49305) filed February 2, 1994).

~~3(ii)By-Laws of Humana Inc., as amended on January 4, 2007 (incorporated herein by reference to Exhibit 3 to Humana Inc.’s Annual Report on Form 10-K for the year ended December 31, 2006).~~

12~~Computation of ratio of earnings to fixed charges.~~

~~31.1Principal Executive Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.~~

~~31.2Principal Financial Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.~~

32~~Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~

3(ii)			Humana Inc. Amended and Restated By-laws, effective as of December 8, 2022 (incorporated herein by reference to Exhibit 3(b) to Humana Inc.’s Current Report on Form 8-K filed on December 8, 2022).
~~101~~ 10.1			Twenty-Fourth Supplemental Indenture, dated March 13, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.’s Current Report on Form 8-K filed on March 13, 2023).
10.2			Twenty-Fifth Supplemental Indenture, dated March 13, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.’s Current Report on Form 8-K filed on March 13, 2023).
10.3			Humana Inc. Executive Severance Policy, effective as of March 1, 2023.
31.1			Principal Executive Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
31.2			Principal Financial Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
32			Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101			The following materials from Humana Inc.'s Quarterly Report on Form 10-Q formatted in ~~XBRL (Extensible~~iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets at ~~September 30, 2017~~March 31, 2023 and December 31, ~~2016;~~2022; (ii) the Condensed Consolidated Statements of Income for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016;~~2022; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three ~~and nine~~ months ended ~~September 30, 2017~~March 31, 2023 and ~~2016;~~2022; (iv) the Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2023 and 2022; (v) the Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2023 and ~~2016;~~2022; and ~~(v)~~(vi) Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104			Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

T a ble of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


					HUMANA INC.
					(Registrant)

Date:			April 26, 2023	~~HUMANA INC.~~By:	/s/ JOHN-PAUL W. FELTER
				~~(Registrant)~~	John-Paul W. Felter

~~Date:~~	~~November 8, 2017~~	~~By:~~	~~/s/ CYNTHIA H. ZIPPERLE~~
			~~Cynthia H. Zipperle~~
			Senior Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer)

6552



	September 30, 2017			December 31, 2016
	(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	9,865		$	3,877
Investment securities	8,622			7,595
Receivables, less allowance for doubtful accounts of $89 in 2017 and $118 in 2016	922			1,280
Other current assets	3,776			3,438
Total current assets	23,185			16,190
Property and equipment, net	1,560			1,505
Long-term investment securities	2,716			2,203
Goodwill	3,281			3,272
Other long-term assets	2,214			2,226
Total assets	$	32,956		$	25,396
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable	$	4,959		$	4,563
Trade accounts payable and accrued expenses	4,888			2,467
Book overdraft	171			212
Unearned revenues	3,447			280
Short-term debt	953			300
Total current liabilities	14,418			7,822
Long-term debt	3,977			3,792
Future policy benefits payable	2,893			2,834
Other long-term liabilities	457			263
Total liabilities	21,745			14,711
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	—			—
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,572,158 shares issued at September 30, 2017 and 198,495,007 shares issued at December 31, 2016	33			33
Capital in excess of par value	2,641			2,562
Retained earnings	13,542			11,454
Accumulated other comprehensive income (loss)	12			(66		)
Treasury stock, at cost, 55,712,062 shares at September 30, 2017 and 49,189,811 shares at December 31, 2016	(5,017		)	(3,298		)
Total stockholders’ equity	11,211			10,685
Total liabilities and stockholders’ equity	$	32,956		$	25,396



	For the nine months ended September 30,
	2017			2016
	(in millions)
Cash flows from operating activities
Net income	$	2,264		$	1,015
Adjustments to reconcile net income to net cash provided by operating activities:
Net realized capital gains	(28		)	(65		)
Stock-based compensation	116			76
Depreciation	303			289
Other intangible amortization	54			59
(Benefit) provision for deferred income taxes	(54		)	54
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:
Receivables	358			396
Other assets	(369		)	(419		)
Benefits payable	396			73
Other liabilities	641			127
Unearned revenues	3,167			2,987
Other, net	114			117
Net cash provided by operating activities	6,962			4,709
Cash flows from investing activities
Acquisitions, net of cash acquired	(10		)	(7		)
Purchases of property and equipment	(376		)	(395		)
Purchases of investment securities	(4,337		)	(4,533		)
Maturities of investment securities	919			1,082
Proceeds from sales of investment securities	2,028			3,319
Net cash used in investing activities	(1,776		)	(534		)
Cash flows from financing activities
Receipts from contract deposits, net	1,931			350
Proceeds from issuance of senior notes, net	985			—
Repayment of commercial paper, net	(153		)	(1		)
Change in book overdraft	(41		)	(118		)
Common stock repurchases	(1,819		)	(75		)
Dividends paid	(162		)	(133		)
Proceeds from stock option exercises and other	61			—
Net cash provided by financing activities	802			23
Increase in cash and cash equivalents	5,988			4,198
Cash and cash equivalents at beginning of period	3,877			2,571
Cash and cash equivalents at end of period	$	9,865		$	6,769
Supplemental cash flow disclosures:
Interest payments	$	124		$	102
Income tax payments, net	$	1,206		$	851



	September 30, 2017					December 31, 2016
	Risk Adjustment Settlement			Reinsurance Recoverables		Risk Adjustment Settlement			Reinsurance Recoverables
	(in millions)
Prior Coverage Years
Premiums receivable	$	127		$	—	$	307		$	—
Other current assets	—			44		—			260
Trade accounts payable and accrued expenses	—			—		(117		)	—
Net current asset	127			44		190			260
Other long-term assets	—			—		6			—
Total prior coverage years' net asset	127			44		196			260
Current Coverage Year
Premiums receivable	30			—		—			—
Trade accounts payable and accrued expenses	(57		)	—		—			—
Net current liability	(27		)	—		—			—
Other long-term assets	29			—		—			—
Other long-term liabilities	—			—		—			—
Net long-term asset	29			—		—			—
Total 2017 coverage year net asset	2			—		—			—
Total net asset	$	129		$	44	$	196		$	260



	Retail		Group and Specialty		Healthcare Services		Total
	(in millions)
Balance at January 1, 2017	$	1,059	$	261	$	1,952	$	3,272
Acquisitions	—		—		9		9
Balance at September 30, 2017	$	1,059	$	261	$	1,961	$	3,281



	For the nine months ended September 30,
	2017			2016
	(in millions)
Balances, beginning of period	$	4,563		$	4,976
Less: Premium deficiency reserve	—			(176		)
Less: Reinsurance recoverables	(76		)	(85		)
Balances, beginning of period, net	4,487			4,715
Incurred related to:
Current year	33,318			34,340
Prior years	(430		)	(525		)
Total incurred	32,888			33,815
Paid related to:
Current year	(28,741		)	(29,768		)
Prior years	(3,745		)	(3,996		)
Total paid	(32,486		)	(33,764		)
Premium deficiency reserve	—			206
Reinsurance recoverable	70			77
Balances, end of period	$	4,959		$	5,049



Reconciliation of the Disclosure of Incurred and Paid Claims Development to Benefits Payable, net of reinsurance

	September 30,
	2017
Net outstanding liabilities
Retail	$	4,166
Group and Specialty	561
Individual Commercial	134
Other Businesses	28
Benefits payable, net of reinsurance	4,889

Reinsurance recoverable on unpaid claims
Retail	70
Total reinsurance recoverable on unpaid claims	70

Total benefits payable, gross	$	4,959



	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016
	(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders	$	499	$	450	$	2,264	$	1,015
Weighted average outstanding shares of common stock used to compute basic earnings per common share	144,215		149,417		145,546		149,321
Dilutive effect of:
Employee stock options	165		210		174		216
Restricted stock	980		1,277		902		1,332
Shares used to compute diluted earnings per common share	145,360		150,904		146,622		150,869
Basic earnings per common share	$	3.46	$	3.01	$	15.56	$	6.80
Diluted earnings per common share	$	3.44	$	2.98	$	15.44	$	6.73
Number of antidilutive stock options and restricted stock excluded from computation	399		658		595		873



Period	Total Number of Shares Purchased (1)(2)	Average Price Paid per Share (3)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)(2)	Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1)
July 2017	—	$	—	—	$	1,050,000,093
August 2017	953,235	253.02		953,235	721,003,128
September 2017	844,568	249.56		844,568	510,251,912
Total	1,797,803	$	249.97	1,797,803